The antimicrobial role of human MAIT cells by Boulouis, Caroline
From the Center for Infectious Medicine, 
Department of Medicine, Huddinge 
Karolinska Institutet, Stockholm, Sweden 







All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Universitetsservice US-AB, 2021 
© Caroline Boulouis, 2021 
ISBN 978-91-8016-127-5 
Cover illustration: Illustration of the thesis findings. Beavers are depicted as the APCs, who 
catch more successfully IgG-opsonized bacteria than non-opsonized one. Beavers that feed 
on IgG-opsonized bacteria are more efficient to activate MAIT cells (magenta cell) due to 
increased MR1 antigen presentation. Activated MAIT cells secrete cytokines (purple and red 
arrows) and cytolytic proteins such as granzyme B and granulysin (green and blue arrows 
respectively) that damage the membrane of carbapenem resistant E. coli (purple bacteria). 
Due to bacterial antibiotic resistance by membrane impermeability, carbapenem antibiotics 
(white dots casted by the little dragon) stay outside of E. coli. However, granzyme B and 
granulysin synergize with carbapenem to restore the bactericidal activity of the antibiotic. 
Finally, S. aureus (orange cocci) secrete LukED toxin (cadmium red dots) that can kill MAIT 
cells. By Caroline Boulouis.  
The antimicrobial role of human MAIT cells 
THESIS FOR DOCTORAL DEGREE (PhD) 
By 
Caroline Boulouis 
The thesis will be defended in public at Karolinska Institutet, room 9Q level 9, Alfred Nobels 
Allé 8, Huddinge, 16th of April 2021 at 9h30 
Principal Supervisor: 
Professor Johan Sandberg 
Karolinska Institutet 
Department of Medicine, Huddinge 
Center for Infectious Medicine, CIM 
 
Co-supervisors: 
Assistant Professor Edwin Leeansyah 
Karolinska Institutet 
Department of Medicine, Huddinge 
Center for Infectious Medicine, CIM 
 
Tsinghua Shenzhen International Graduate 
School 
Institute for Biopharmaceutical and  
Health Engineering 
 
Associate Professor Peter Bergman 
Karolinska Institutet 
Div. Clinical Microbiology 
Department of Laboratory Medicine 
 
Opponent: 
Research director Agnès Lehuen 




Professor Mikael Karlsson 
Karolinska Institutet 
Department of Microbiology, Tumor and Cell 
Biology 
 
Assistant Professor Keira Melican 
Karolinska Institutet 
Department of Neuroscience 
Swedish Medical Nanoscience Center 
 
Professor Marianne Quiding-Järbrink 
University of Gothenburg 
Department of Microbiology and Immunology 
































MAIT cells are unconventional T cells that have characteristics of both innate and adaptive 
immunity. Their fast mobilization and wide distribution in tissues make them part of the first 
line of defense against infection. MAIT cells recognize riboflavin-related metabolites 
produced by bacteria and presented by MR1. However, they can also sense viral infection 
through non-specific activation by cytokines.  MAIT cells respond rapidly with secretion of 
cytokines and degranulation of cytolytic molecules, and play an important role in immune 
defense. This thesis work aimed to further explore the function of MAIT cells in different 
contexts.  
First, we explored the interaction between humoral IgG responses and MAIT cells in 
antibacterial immunity. Here, MAIT cell responses to IgG-opsonized bacteria were compared 
to responses against non-opsonized bacteria. MAIT cell responses against opsonized 
Escherichia coli were stronger, with an increased magnitude and faster kinetics. Furthermore, 
MAIT cells were activated at lower bacterial doses when opsonized. We deciphered the 
mechanism responsible for the MAIT cell boost of function and showed that FcγR triggering 
by the opsonized bacteria was essential to increase MR1 antigen presentation. The boost of 
function was validated in a vaccine setting, where we used sera from individuals before and 
after vaccination against Streptococcus pneumoniae to opsonize one vaccine strain. MAIT 
cell functions were boosted when stimulated with S. pneumoniae opsonized with sera drawn 
after vaccination. In the second project, we investigated the cytolytic mechanisms used by 
MAIT cells against E. coli. Interestingly, MAIT cells not only killed E. coli-infected cells but 
also controlled cell-associated bacterial load through degranulation. More precisely, 
Granzyme B (GzmB), Granulysin (Gnly), and perforin were involved in the killing. MAIT 
cell activity was maintained against carbapenem-resistant E. coli (CREC). CREC strains use 
two main mechanisms of resistance: production of carbapenemases that inactivate 
carbapenem antibiotics, and membrane impermeability by porin-loss or over-expression of 
efflux pumps that block antibiotic penetration in the bacteria. Interestingly, MAIT cell-
derived Gnly and GzmB were able to damage the membrane of free-living CREC. This effect 
was further enhanced by the addition of carbapenem antibiotic, suggesting a synergy between 
the cytotoxic proteins and the antibiotic. This also implied that MAIT cells may overcome the 
impermeability mechanism of resistance of CREC. In the third project, we investigated if 
some bacteria can adapt to escape from MAIT cell responses through immune evasion 
mechanisms. Staphylococcus aureus produces the pore-forming toxin leukotoxin ED 
(LukED) that binds to CCR5. We found that MAIT cells were hypersensitive to LukED and 
this was due to very high expression of CCR5 on MAIT cells. Within the T cell pool, MAIT 
cells were the most severely depleted population indicating that LukED secretion constitutes 
an immune evasion mechanism from MAIT cell recognition. 
In conclusion, these findings indicate that MAIT cell responses are boosted against IgG-
opsonized pathogens. Furthermore, MAIT cell cytolytic activity is maintained against CREC, 
and GzmB and Gnly synergize with carbapenem antibiotics to kill free-living CREC. Finally, 
some bacteria have developed means to evade MAIT cell responses, and this includes LukED 
secretion by S. aureus, which strongly targets MAIT cells. Overall, this thesis work enhances 
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1.1 THE IMMUNE SYSTEM IN THE LIGHT OF MAMMALIAN EVOLUTION 
Mammals, including humans, have developed tools and mechanisms to protect us against 
many threats. The immune system is a formidable network able to defend us against 
microorganisms (bacteria, viruses, fungi and parasites), the toxins they produce and the 
damage they can make. The immune system can also fight internal threats such as cancerous 
cells. This network has evolved over millions of years to achieve the level of sophistication it 
has reached in humans and other present-day mammals. Diverse features have been 
integrated through evolution and those are briefly described in the next paragraphs.  
Classically, the immune system is divided into two branches: the innate and adaptive 
branches. The first reacts rapidly and non-specifically, while the second recognizes specific 
epitopes and allows building of long-lasting immune memory. Most of the living organisms 
on Earth are relying on the innate immune system for defense against infectious threat (1). 
This is not limited to the animal kingdom but also extends to prokaryotes (2), plants (3, 4), 
and is also present in fungi (5). The innate immunity of invertebrates (insects, mollusks, etc) 
relies on cellular events such as phagocytosis of foreign material, and the secretion of 
antimicrobial peptides (AMPs) that carry antibacterial or antifungal properties, and differs 
between species. Additional mechanisms include the production of reactive-oxygen species 
(ROS) and nitric oxide (NO). The discrimination between the host and the invader is 
achieved through the sensing of pathogen-associated molecular patterns (PAMPs) such as 
lipopolysaccharide (LPS), peptidoglycan, unmethylated CpG DNA by the pattern recognition 
receptors (PRR). The PRRs are germline encoded and include Toll receptors, which are the 
equivalent of Toll-like receptors (TLR) in mammals (1, 6-9). PRR triggering leads to 
activation of host defense mechanism. This system allows recognition of broad groups of 
pathogens but is unable to discriminate between different strains. Vertebrates have similar 
innate detection systems (6). 
The first hint of adaptive features appeared in jawless vertebrates with the development of a 
system to recognize diverse antigens using variable lymphocyte receptors (1). 400 million 
years ago, a breakthrough event happened in vertebrates: the appearance of the adaptive 
branch of immunity with the capacity to recognize specific antigens and the formation of 
long-term memory cells. B (bursa of Fabricius) and T (thymus) lymphocytes are the two 
main cellular lineages of adaptive immunity (10). The capacity of the B cell receptor (BCR) 
and T cell receptor (TCR) to undergo V(D)J recombination provide a diverse repertoire with 
capacity for specific antigen recognition. Following an infection, some T and B cell clones 
will be retained as memory cells that can be reactivated faster in the event of re-infection. 
Another major event in vertebrate immunity is the capacity to discriminate self versus non-
self introduced by the major histocompatibility complex (MHC), which present antigens to 
conventional T cells. This advancement comes with the price of potential self-reactivity (10). 
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1.2 THE HUMAN IMMUNE SYSTEM  
Anatomic and chemical barriers such as skin and mucosal surfaces are the fist line of defense 
against infection. Upon pathogen breach of these barriers, the cellular component of the 
innate immunity takes the lead of the response. Local macrophages and dendritic cells (DCs) 
are able to take up bacteria through phagocytosis and can kill ingested pathogens. Upon PRR 
triggering, those cells secrete diverse cytokines, chemokines, and AMPs that contribute to 
local inflammation, immune cells recruitments, and pathogen killing (Luster, 2002). Within 
minutes, neutrophils, which are crucial effector cells, are recruited to the site of infection 
followed by monocytes (11, 12). The innate branch also includes innate lymphoid cells 
(ILCs) that amplify the inflammatory signals, and natural killer (NK) cells that have cytotoxic 
properties and can lyse infected cells (13, 14). Lastly, the complement system, composed of 
soluble proteins present in blood and fluids, helps pathogen clearance upon activation (15). 
The immune response is tailored according to the kind of pathogen our body encounters and 
fine-tuned to the danger signals activated by the threat.  
While the innate immune cells may be able to clear pathogens, in some cases they need help 
from the adaptive arm of the immune system. Establishment of the adaptive immune 
response takes time, usually 7-10 days, and the innate immunity has to hold until adaptive 
lymphocytes come to the rescue (7). Communication and interaction between the innate and 
adaptive branches is essential for the downstream response. DCs are professional antigen-
presenting cells (APC) that can migrate to secondary lymphoid tissues (lymph node, spleen, 
Peyer’s patches) to present foreign antigen to naïve T cells. Specific clones will go through 
clonal expansion and differentiate into effector T cells before infiltrating the site of infection 
(16). Effector T cells are short-lived but some will remain as long-lived memory T cells. B 
cells get activated with the help of follicular DCs and T follicular helper (Tfh) cells and 
differentiate into plasma cells for antibody production or memory B cells. Affinity maturation 
is an important step happening in the germinal center of the lymph node to improve affinity 
of antibodies for their cognate antigen (17). 
On the border between the innate and adaptive branches of cell-mediated immunity we find 
the family of unconventional or innate-like T cells, which display both innate and adaptive 
characteristics. It comprises ɣδ T cells, CD1-restricted T cells such as invariant natural killer 
T (iNKT) cells, and MR1-restricted T cells primarily including the Mucosa-Associated 
Invariant T (MAIT) cells (18-20). Contrary to classical T cells, the innate-like T cells 
recognize non-peptide antigens and are donor-unrestricted. Their abundance means they can 
rapidly respond in large numbers and sustain protection of the host while the adaptive 
immune response is still maturing (18). 
1.3 MUCOSA-ASSOCIATED INVARIANT T (MAIT) CELLS 
MAIT cells are perhaps the most abundant and significant subset of unconventional T cells, 
and are the primary focus of this thesis.   
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1.3.1 Towards ligand discovery  
MAIT cells express a semi-invariant αβTCR. The TCR α-chain invariably contains the Vα7.2 
segment and is highly conserved between individuals. Vα7.2 is encoded by TRAV1-2 and 
combined with a limited set of J (TRAJ 12/20/33) segments. The TCRα chain is paired with a 
limited Vβ repertoire. Thus, the MAIT cell TCR diversity is very limited compared to the 
huge repertoire of conventional T cells (21-23). The MAIT cell TCR recognize small 
microbial metabolites presented by the MHC-Ib-related protein (MR1). The most potent 
activating ligands known to date are the vitamin B2 (riboflavin)-related metabolite antigens 
(24). Before continuing with a more in-depth description of MAIT cell ligands below, let us 
briefly touch upon the evolutionary aspects of the recognition of such metabolites. Riboflavin 
is necessary for the basic metabolism of animals and microorganisms. The riboflavin 
biosynthesis pathway is conserved in many microbes, whereas it is not present in mammals 
(or any animals). Bacteria that do not synthetize riboflavin must be able to take it up from the 
local environment (as riboflavin is critical for bacterial survival and growth) and also have the 
advantage of largely avoiding MAIT cell TCR recognition (25-27). 
The folic acid (vitamin B9) metabolite 6-formyl pterin (6-FP) was the first MR1 ligand 
discovered (28), later followed by its acetylated and more stable version Ac-6-FP (24). 
Vitamin B9 metabolites are able to provoke MR1 egress to the cell surface, but do not 
activate MAIT cells (24). Vitamin B2 (riboflavin)-related derivatives (28) and metabolites 
(29) as MR1 ligands were discovered around the same time. The reaction of the metabolite 5-
amino-6-D-ribitylaminouracil (5-A-RU) with host-derived methylglyoxal or glyoxal create 
the unstable antigen 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU) and 5-(2-
oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU). These unstable pyrimidines bind to 
MR1 trough covalent Schiff base formation (29). If left unbound, the pyrimidine 
intermediates are converted into ribityl lumazine that weakly activates MAIT cells without 
Schiff base formation (28, 29). A crucial component of the activating ligand is the presence 
of the ribityl chain that is essential to bind the MAIT TCR and activate MAIT cells (29, 30). 
In addition to these natural MR1-presented ligands, synthetic drugs can also bind to MR1. 
Diclofenac metabolites potently activate MAIT cell with neither Schiff base bond formation 
nor upregulation of MR1 cell surface expression. On the other hand, salicylates are potent 
competitive inhibitors, nearly as potent as Ac-6-FP (31). A recent study (32) found a new 
mechanism of MAIT cell antagonism. Through an in silico screen, the compound DB28 (3-
([2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4yl]formamido)propanoic acid) was identified as a 
potent non-microbial antagonist able to reduce MR1 cell surface expression by blocking MR1 
egress from the endoplasmic reticulum (ER). DB28 is not able to form Schiff base with MR1 
but stabilize it through hydrophobic interactions. 
1.3.2 The MR1 antigen presentation pathway 
Hashimoto et al. discovered MR1 in 1995 (33). MR1 is thought to have appeared about 170 
million years ago and is a highly conserved protein in placental mammals (34-36). Some 
mammals have lost MR1 during the course of evolution: armadillo, carnivores and 
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lagomorphs (rabbits) lack MR1 (34). No MAIT cells are found in those species but 
compensatory mechanisms may exist (34). Human MR1 shares the highest homology with 
those of non-human primate and is more closely related to several bats MR1 (>80% 
homology) (37), than to mouse or rat homologs. MR1 is widely expressed in human cells, 
MR1 mRNA expression was detected in all tissues examined, including PBMC, thymus, 
lung, liver, heart, brain, small intestine, colon, placenta, ovary, testis, prostate, kidney, 
pancreas, spleen, and skeletal muscle (33).  Unloaded MR1 is retained in the ER with the help 
of tapasin and tapasin-related protein chaperones, in a conformation open to ligand binding 











Figure 1. The MR1 antigen presentation pathway. Exogenous riboflavin-related metabolites reach the ER and 
bind to MR1 molecules through Schiff base formation (1). Loaded MR1 translocates to the cell surface (2) and 
can be recycled to endosomal compartments where it can be charged with new ligands (3). Ligands derived from 
intracellular bacterial infection may be loaded in the endosome or in the ER (4). APC: antigen presenting cell; 
ER: endoplasmic reticulum. Created with BioRender.com.  
The translocation signal is given by the Schiff base formation between the Lys43 of MR1 and 
the ligand. Some ligands bind to MR1 without Schiff base formation, such as diclofenac 
metabolites, 6-FP and ribityl lumazine. They are less efficient in provoking MAIT cell egress 
and fail to activate MAIT cell to the same extent as 5-OP-RU (29, 31). It is currently 
unknown how the ligands reached the ER but both extracellular and intracellular sources of 
ligands can be loaded on MR1 in this compartment (38, 40). Exogenous ligands reach the ER 
and bind to MR1 within 10 minutes of exposure, and the resulting complex is then expressed 
at the cell surface within two hours (39). Ligands derived from intracellular bacterial 
infection may be preferentially be loaded in endosomal compartments, but this is not fully 
elucidated yet (40, 41). The MR1-ligand complex remains at the cell surface for several 
hours. The cell surface expression is dependent on the continual delivery of new MR1-loaded 
ligand, which is different from MHC class I molecules whose the residence time at the 
plasma membrane depends primarily on the ligand affinity. Thus, when the pathogen is 
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cleared and the ligand levels drop, the MR1 surface expression decreases (42). Once MR1 is 
internalized, it can either be degraded or acquire new ligands in the recycling pathway (38, 
40, 41, 43). This step may occur in the endo/lysosomal compartment since the removal of the 
Schiff base bond requires low pH (44). This tight mechanism of regulating MR1-cell surface 
availability constitutes a real-time scanning mechanism by the APC for antigens that can be 
detected by MAIT cells (42). 
Two MAIT cell deficient patients have thus far been described (45, 46). Howson et al (46) 
found a homozygous point mutation Arg31His in MR1 that impaired riboflavin-related 
metabolite ligands binding to MR1. Folic acid (pterin)-based ligands such as Ac-6-FP were 
still able to bind this mutated MR1 and provoke its egress at the cell surface. The patient was 
devoid of circulating MAIT cells, but seemed to compensate this deficiency with an 
expanded ɣδ T cell population (46). 
1.3.3 Identification of MAIT cells by flow cytometry  
MAIT cell identification was initially done by flow cytometry with the expression of CD3, 
Vα7.2 and CD161. This was commonly accompanied with CD26, CD8 and IL-18R, which 
are also highly expressed by MAIT cells (47, 48). Once the MAIT cell antigens were 
identified, this allowed the development of new technology able to accurately identify MAIT 
cells: MR1 tetramer loaded with 5-OP-RU (49). This reagent became available to the field in 
2016 through the NIH Tetramer Core Facility. 
1.3.4 MAIT cell localization and residency  
MAIT cells and bacteria have co-evolved through mammalian evolution, such that MAIT cell 
distributions across tissues seems to reflect the presence of the microbiota and exposure to 
microbial pathogens (34, 50). MAIT cells are enriched at different barrier sites, including 
mucosal tissues: in the oral mucosa (51), all along the gastrointestinal tract (47, 49, 52-54), in 
the liver where they can be up to 50% of T cells (47, 54), in the lungs (55), in the skin (56) 
and in the female genital tract (57). MAIT cells mostly lack expression of CCR7 (47), an 
important receptor for entry into secondary lymphoid organs (58) and therefore are scarce in 
those sites, including lymph nodes (47), but they are present in the thoracic duct lymph (59). 
In blood, MAIT cells constitute 1-10% of the circulating T cell population of healthy donors 
(47). It is interesting to note that the MAIT cell frequency in circulation varies quite 
substantially between healthy humans. The basis for this is not clear, but may reflect 
exposure to distinct microbiota as well as infection history. It could also be linked to genetic 
background and inherited or inborn error of immunity.   
Peripheral blood MAIT cells have tissue-homing properties and this reflects their distribution 
in the body (Figure 2). CCR9 and CCR6 guide their homing to the gut, CXCR6 to the liver 
(47), CXCR3 to the lung (59) and CCR5 (47) and CCR2 to inflamed tissues (60). MAIT cells 
also express CCR4, which may confer skin-homing capacity (61), and CXCR4 (47). 
Recently, the expression of CXCR5, which supports homing to germinal centers, was 
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detected at low levels in blood MAIT cells (62), suggesting their possible migration to such 







Figure 2. Chemotaxis properties of MAIT cells. Chemokine expression on blood MAIT cells and their tissue 
homing capacities. Created with BioRender.com. 
How and when MAIT cells are seeded in tissues and if MAIT cells form a true tissue-resident 
population is still not entirely clear. Parabiosis experiments in mice show that tissue MAIT 
cells do not recirculate (63, 64). Deciphering if the same applies to humans remains to be 
explored. One study found that human MAIT cells express a stronger tissue residency 
program in the liver compared to blood and that the tissue localization affects gene 
expression (64), while another study did not find such MAIT cell tissue residency signature in 
the liver (65). One hypothesis is that tissue MAIT cells may be a mixture of resident and 
circulating cells (51, 66). In the oral mucosa, the Jα chain usage in MAIT cells was more 
diverse than their matched blood counterpart (51). Furthermore, MAIT cells are found in the 
thoracic duct, which drains the lymph coming from nearly all organs in the body. The TCR 
clonotypes of MAIT cells in the thoracic lymph was found to be similar to those seen in 
blood. This suggests that they may be able to leave the tissue and re-circulate, or that MAIT 
cells are able to migrate to lymph nodes in a CCR7-independent manner (59).  
1.3.5 MAIT cell development and homeostasis 
MAIT cell development and maturation occurs in two main steps: selection in the thymus by 
MR1-expressing thymocytes, followed by expansion in the periphery. It is likely that the 
microbiota colonization is crucial for MAIT cell development, since germ-free mice are 
devoid of MAIT cells (63, 67-71). The exposure to microbiota must occur early in life or 
MAIT cell will not develop (71). Although it is still unclear if MAIT cells are selected by 
empty MR1, MR1/5-OP-RU complexes or by self-antigens (72), 5-OP-RU can travel from 
the periphery to the thymus and bind to MR1 (63, 73). Koay et al (69), described a three-
stage development process of human MAIT cells, based on the expression of CD161 and 
CD27. MAIT cells at development stage 1 are located in the thymus, display a naïve 
phenotype and lack PLZF expression. Under the control of PLZF, stage 2 MAIT cells 
migrate outside the thymus to continue their maturation to stage 3 in the periphery. T-bet is 
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probably also important for MAIT cell development since MAIT cells were found to be very 
low in numbers in a recently described T-bet deficient patient (74). Some functions such as 
tissue homing may be imprinted already in the thymus. For instance, MAIT cells have a 
gradual expression of chemokine receptors CCR5 and CCR6 during thymic maturation (75). 
Functionally, some stage 3 thymic MAIT cells can produce cytokines but at a lower level 
than the stage 3 cells in blood (69), highlighting the importance of peripheral maturation. In 
humans, the seeding of MAIT cells in tissues may occur before birth, since they have been 
found in small intestine, liver, and lung of second trimester fetal tissues (76). At birth, the 
percentage of MAIT cells in blood is lower than in healthy adults (68, 70). After birth, the 
MAIT cell population increases gradually with age in the peripheral blood (47, 69), having a 
low expansion rate during infancy to finally reach a plateau around the age of six (70). Within 
two months after birth, half of the MAIT cells have already acquired a memory phenotype 
(70). The MAIT cell percentage remains relatively stable in adults, before starting to 
gradually decline during ageing. The MAIT cell reduction in the elderly is balanced by the 
expansion of some clonotypes. Furthermore, full functionality of MAIT cells is maintained in 
aged individuals (77). 
MAIT cells express a high level of IL-7Rα (78), the receptor for IL-7, a well-known cytokine 
for maintenance of lymphocyte populations (79). The importance of IL-7 for MAIT cell 
development and maintenance is still unknown; although recent findings indicate that 
recombinant IL-7 treatment in humans can expand the peripheral blood MAIT cell pool (80, 
81).  
1.3.6 MAIT cell activation phenotype, effector functions and roles in 
infection 
MAIT cells express diverse transcription factors that shape their functionality. T-bet, Eomes 
and Blimp1 frame their Th1 phenotype and the secretion of IFNγ/TNF along with their 
cytotoxic capabilities through the release of perforin, granzyme B (GzmB) and granulysin 
(Gnly) (82, 83). The expression of RORγT and STAT3 underpins their Th17 phenotype and 
the production of IL-17A and IL-22 (84). PLZF is crucial for MAIT cell development (69), 
but is also associated to the high expression of IL-12R and IL-18R on MAIT cells (66). 
MAIT cells also express the transcription factor Helios but its role remains unclear (85). 
1.3.6.1 MAIT cell activation 
MAIT cell activation occurs by two main ways: TCR-dependent and TCR-independent, the 
latter being trough cytokine stimulation. These two pathways can also synergize to activate 
MAIT cells.  
TCR triggering is essential for MAIT cell activation but is not sufficient to fully engage all 
MAIT cell functions (82, 86, 87). To be fully activated, MAIT cells need co-stimulation 
signals, via CD28, TLRs or cytokines (88-90). Indeed, in mice, the administration of 5-OP-
RU alone in the absence of TLR agonists does not induce MAIT cell proliferation, activation 
or accumulation in the lung (90, 91). In regard of the broad expression of MR1, this 
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mechanism of regulation is essential to avoid over activation towards components of the 
microbiota that also produce riboflavin metabolites (66). Thus, MAIT cells are “poised to 
maintain homeostasis in the presence of commensals” (90).  
Cytokines can activate MAIT cells in an MR1-independent manner. MAIT cells express a 
high level of IL-12R (65, 86), IL-18R (27), IL-15R, IFNαR (65), and DR3 (92), and are 
activated by their ligands, respectively IL-12, IL-18, IL-15, IFNα/β and TNF-like protein 1A 
(TL1A). IL-12 and IL-18 combination was first described to activate MAIT cells without 
TCR triggering (93). Later, IL-15 (94) and type I interferons (IFNα/β) (95, 96) in synergy 
with IL-18, and TL1A (87) in combination with IL-18, IL-12 and IL-15 were also found to 
activate MAIT cells. Cytokine-mediated activation narrows the MAIT cell functional profile 
to the secretion of IFNγ and GzmB (96).  
Synergy between TCR triggering and cytokine activation brings the full range of MAIT cell 
functions (54, 61, 86, 87, 89, 93, 97), which is the case in bacterial (83, 98) and fungal (85, 
99, 100) infections. TCR-dependent activation is known to occur within 6 hours of bacterial 
stimulation, while the synergy of TCR and cytokine activation happens later (93). Once fully 
activated, MAIT cells express several activation markers such as CD69, CD25, CD38, HLA-
DR (27, 101, 102), and produce a wide array of effector molecules. Upon in vitro bacterial 
stimulation, blood MAIT cells secrete IFNγ, TNF, IL-17A and release the cytolytic proteins 
GzmB, perforin, Gnly (57, 83, 98, 103). MAIT cells can also secrete chemokines, including 
CCL3, CCL4, CCL20, CXCL9, CXCL10, CXCL11 and IL-8 (CXCL8) (78, 86, 104).  
MAIT cells can be activated by numerous types of APCs: monocytes, macrophages, DCs, 
and B cells but the responses will differ depending on the type of APC (98, 105-107). 
Stimulation with non-professional APCs, such as epithelial cells, will drive mainly TCR-
dependent responses (108). 
Cytokine production in tissue MAIT cells differs from their blood counterparts (50, 51, 53, 
57, 65, 78, 97, 109). Tissue MAIT cells have a more pronounced Th17 phenotype with high 
production of IL-17 in the bronchoalveolar lavage (BAL) of pneumonia patients (110), in the 
female genital tract (57), and in the oral mucosa (51) of healthy individuals. In the liver, 
MAIT cells are more responsive to IL-12 and IL-18 than in the blood (65).  
1.3.6.2 Cytotoxic properties of MAIT cells 
MAIT cells are well known for their ability to kill bacteria-infected cells in a TCR-dependent 
manner (82, 83, 103) (Figure 3). Cytotoxic lymphocytes share a conserved mechanism of 
killing target cells: the release of granules containing numerous cytotoxic proteins (111). 
Upon appropriate stimulus such as antigen detection, the granule content (perforin, 
granzymes and Gnly) will be released into the synapse formed with the target cell. Perforin, a 
pore-forming toxin is first needed to perforate holes and hence permeabilize the target cell 
membrane. It allows the granzymes and Gnly to enter the cytoplasm and promote cell death 
by apoptosis (111). Granzymes are serine proteases that cleave specific substrates, unique for 
each granzyme subtype (112). MAIT cells express GzmB, GzmA and GzmK (83). GzmB is a 
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potent pro-apoptotic granzyme that cleaves many essential mammalian proteins (111). It also 
targets bacterial enzymes and proteins necessary for oxidative stress defense, metabolism and 
protein synthesis, thus acting as a powerful antibiotic (113, 114). GzmB can also digest 
bacterial toxins (Leon, 2020). GzmA and GzmK have pro-inflammatory properties, although 
GzmA may also induce apoptosis through caspase-3-independent pathway (111, 112). Gnly 
is a saposin-like protein that creates holes in cholesterol poor membrane, thus it preferentially 
targets bacteria rather than human cells. It allows GzmB penetration into the bacteria, 
unleashing its antimicrobial properties (114). Rodents are devoid of Gnly, thus MAIT cell 

















Figure 3. Antimicrobial properties of MAIT cells (from (116)). MAIT cells produce cytokines that help recruit 
other immune cells, induce immune cell maturation and directly control bacterial load. Cytotoxic molecules 
released by MAIT cells kill infected cells but also kill intracellular and extracellular bacteria, including 
carbapenem-resistant ones (see paper II). Created with BioRender.com. 
At resting steady state, MAIT cells express GzmA and GzmK but only low levels of perforin 
and Gnly, and little GzmB (83, 103). Upon activation, MAIT cells upregulate GzmB, perforin 
and Gnly and degranulate as seen with surface staining of CD107a. Importantly, MAIT cells 
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can be armed in response to different stimuli. Indeed, MAIT cells pre-activated with IL-7 
(82), fixed bacteria (83) or 5-OP-RU in presence of IL-7 and IL-2 (paper II; (117)) display 
higher cytotoxic capacity than resting MAIT cells. 
MAIT cells also secrete IL-26 upon TCR and cytokine activation (87, 118), a potent 
antimicrobial cytokine, which is able to puncture bacterial membranes and provoke bacterial 
cell death (119). MAIT cells also secrete CCL20, CCL9 and CXCL10 that display 
antimicrobial properties (120-122). It is still unknown how these proteins participate in MAIT 
cell antimicrobial defense. 
1.3.6.3 MAIT cells in bacterial and viral infection 
MAIT cells play a major role in fighting bacterial infections, as seen in vivo or in vitro (20, 
116). Figure 3 summarizes the antimicrobial functions of MAIT cell. In animal models, 
MAIT cells protect against infection and control bacteria burden against 
Legionella longbeachae, in a mechanism dependent on IFNγ, GM-CSF and MR1 (123). 
MAIT cell control of infection was also shown in Francisella tularensis, 
Klebsiella pneumoniae and Mycobacterium tuberculosis (MTB) infection (124-127). In mice, 
MAIT cell-derived IFNγ helps to clear intracellular infection through the induction of nitric 
oxide in macrophages (Figure 3) (124, 125). MAIT cells can also expand at the site of 
infection (91, 123, 124). Interestingly, upon vaccination with 5-OP-RU in combination with 
TLR agonists or IL-23, MAIT cells expand and confer an early protection against Legionella 
infection (91, 123, 128). In contrast, vaccination with 5-OP-RU did not improve the control 
of acute MTB infection, while its application during chronic infection helps MAIT cell 
recruitment and bacterial control through IL-17A (126). Thus, MAIT cells may have a 
potential role in vaccination. MAIT cells are also able to coordinate the response to 
pathogens. During F. tularensis infection of the lung, MAIT cells produce GM-CSF that 
induces the differentiation of CCR2+ monocytes into monocyte derived-DC that in turn 
recruit CD4+ T cells (129). Finally, a detrimental role of MAIT cells in infection has also 
been proposed. In Helicobacter pylori infection, MAIT cell accumulated in the gastric 
mucosa and worsened the outcome of the disease (52). Furthermore, the role of MAIT cells 
in MTB is ambiguous due to inconsistent findings in the control of MTB infection by MAIT 
cells in different animal models (125, 126, 130).  
In humans, MAIT cells are activated by bacteria producing riboflavin, such as 
Escherichia coli (27, 98), K. pneumoniae, Staphylococcus aureus (27), Streptococcus 
pneumoniae (105, 131), Salmonella spp (101, 102, 132), and Neisseria gonorrhoeae (133). 
MAIT cells often tend to decrease in peripheral blood during infection (27, 55, 101, 102, 134-
136), except in some cases where they remain stable (137, 138). Challenge studies with 
Salmonella enterica subsp enterica serovar Typhi (S. Typhi) (102) and Salmonella enterica 
subsp enterica serovar Paratyphi A (S. Paratyphi A) (101) showed that blood MAIT cells 
declined in numbers and were activated upon infection. The secretion of cytokines by MAIT 
cells is key in some settings. IFNγ and TNF responses by MAIT cells prevent nasal 
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colonization of S. pneumoniae (139). Furthermore, MAIT cell-derived IFNγ is important for 
MTB immunity (74).  
MAIT cell cytokine production also facilitates the recruitment of other immune cells, and 
further activates neighboring cells that ultimately defeat the infection ((116); Figure 3). First, 
MAIT cells probably have the ability to help B cells. The supernatant of activated MAIT cells 
stimulates B cell production of IgG, IgA and IgM and supports the differentiation of memory 
B cells into plasmablasts (140). A follow-up study found the presence of CXCR5+ MAIT 
cells in tonsils next to the germinal centers, exhibiting a Tfh phenotype (PD-1+, ICOS+, 
Bcl6+ and IL-21 secretion) (62). Furthermore, animal studies showed that MAIT cells 
provide help to B cells through cytokine secretion and stimulate pathogen-specific antibody 
production (62, 141, 142), as seen in vitro. MAIT cells also induce maturation of monocyte-
derived and primary DC via the CD40-CD40L axis (106). Finally, MAIT cells interact with 
neutrophils, although the two studies on this topic are not consistent, probably due to 
differences in the experiment protocols. Davey et al. (143) found that after antigen 
presentation by the neutrophils, MAIT cells secrete IFNγ, TNF and GM-CSF that can make 
neutrophils cross-present antigens to CD8+ and CD4+ T cells. In contrast, Schneider et al. 
(144) found that neutrophils can suppress MAIT cell activation and that highly activated 
MAIT cells kill neutrophils. 
Human primary immune deficiency brings insights regarding the important roles of MAIT 
cells in antimicrobial immunity. An individual lacking MAIT cells due to mutations in MR1 
was recently identified (46). Despite compensatory increase of ɣδ T cells population, the 
individual had a history of unexplained infections revealing immunodeficiency: treatment-
refractory Campylobacter infection, development of secondary bacterial pneumoniae after 
viral infection, and human papillomavirus activation after being tattooed. Thus, MAIT cell 
absence weakens immune protection. In the case of STAT3 deficiency, an important factor of 
Th17 differentiation, MAIT cells are characterized with impaired IL-17A and IL-17F 
production while the level of IFNγ and TNF are normal (84). STAT-3 deficient patients are 
susceptible to pathogens for which Th17 immunity is crucial including Candida albicans and 
S. aureus (84) and both these microbes activate MAIT cells (27, 98). Of note, MAIT cells 
express high level of IL-23R, and IL-23 is important for the maintenance of STAT3 
expression in MAIT cells, thus maintaining their Th17 phenotype (84). 
Viruses are unable to activate MAIT cells in an MR1-dependent way. However, the release of 
cytokines during viral infection allows MAIT cell activation, particularly through IL-18 in 
combination with IL-12, IL-15 and IFNα/β (93, 95, 96, 145). In many viral infections, such as 
dengue, zika, hepatitis C, hepatitis B and D co-infection, human immuno-deficiency virus 
(HIV), influenza, measles, and severe acute respiratory syndrome coronavirus-2 (SARS-
CoV-2), MAIT cells are activated and display an activated phenotype with higher expression 
of CD25, CD38, HLA-DR, PD-1, CD69, TIGIT (95, 96, 145-153). During such infections, 
MAIT cell numbers in blood decline, either due to death by apoptosis (146, 152) or 
recruitment to inflamed tissues, for example, into the lungs as seems to be the case in SARS-
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CoV-2 infection (149). In mice, MAIT cells conferred protection against lethal influenza A 
virus infection, while MR1 deficient mice (MR1-/-) died from the infection (95).  
1.3.6.4 Tissue repair function 
Recently, at the gene expression level, MAIT cells were found to express a tissue repair 
transcriptome signature when stimulated through their TCR alone, or TCR combined with 
cytokines. This is accompanied by the upregulation of genes coding for Furin, CCL3, GM-
CSF and certain growth factors (87, 90). The wound-healing activity of MAIT cell was 
confirmed in vitro (87), and in vivo (71). Indeed, 5-OP-RU topical application on mouse skin 
before wounding was enough to increase MAIT cell repair properties (71). Thus, MAIT cells 
can promote barrier integrity in homeostasis and healing during tissue injuries (71, 87, 90). 
1.3.7 MAIT cell heterogeneity 
A T cell clone is defined by a unique TCR sequence. The MAIT cell TCR is composed of the 
α-chain with very little diversity, paired with a limited β-chain diversity (21-23, 154). MAIT 
cells appear to have slightly different functional responses to microbes according to the TCRβ 
chain diversity (85). Moreover, during challenge with S. Paratyphi A in human volunteers, 
there is an evolution of the MAIT cell TCRβ repertoire. Some clonotypes expanded, were 
more activated during the infection and displayed higher avidity than the others (101). 
Interestingly, alterations in the MAIT cell clonotype distribution can occur also during acute 
viral infection, as recently observed in acute HIV-1 infection (155).  
MAIT cells express some NK cell-associated receptors such as CD56, CD84, CD94, 
NKG2D and NKp80. MAIT cells expressing CD56 or CD84 displayed a different 
transcription factor profile and respond more strongly after IL-12 and IL-18 stimulation (85). 
Finally, MAIT cells express CD8 or CD4, and can also be double negative for these markers 
(DN). CD4+ MAIT cells are a very rare population. The CD8+ MAIT cell cytokine response 
is stronger than that of DN MAIT cells. CD8+ MAIT cells downregulate CD8 over time 
during in vitro culture. In vivo, CD8+ MAIT cells accumulate before DN MAIT cells in fetal 
development. Thus, we recently proposed that DN MAIT cells are derived from CD8+ MAIT 
cells (156). 
1.3.8 Other MR1-restricted T cells 
MAIT cells are the main representative of MR1-restricted T (MR1T) cells but are not the 
only one. Atypical MAIT cells are phenotypically distinct and do not express TRAV1-2 but 
still recognize folic acid or riboflavin metabolites or could be MR1-autoreactive. These cells 
may also lack PLZF, a central MAIT cell transcription factor, and constitute a very rare 
population (0.01% in blood). Other MR1T cells have been described and more research is 
needed to fully understand their role (19, 20, 23, 154). 
 
 13 
More recently, MR1 was described to present metabolites from cancerous cells to a T cell 
clone but the ligand is yet to be identified (157). This may open the path for the discovery of 
possible endogenous MR1 ligand. 
In the next section, we will turn our attention to the bacterial side and particularly to antibiotic 
resistant bacteria. 
1.4 ANTIMICROBIAL RESISTANCE 
Antibiotic resistance exists in the wild but the overuse and misuse of antibiotics in the clinic 
and in the farming industry have led to an exponential growth of antibiotic resistant bacteria 
all over the world (158, 159). It is a serious threat that claims thousands of human lives each 
year and could take millions in the near future, particularly in developing countries (158). The 
economic load is also a concern that will keep growing in the following years (158). 
Furthermore, if antibiotic drugs do not work anymore, many medical interventions 
(chemotherapy, surgery, Caesarean-section) will be at risk, undermining our current 
healthcare system (158). Antibiotic resistance is affecting all classes of antibiotics and the 
development of new classes is outpaced by the emergence of drug-resistant bacteria. In this 
thesis-work, we used carbapenem-resistant E. coli (CREC) in several experiments. 
Carbapenems belongs to the β-lactam family of antibiotics. 
1.4.1 β-lactam antibiotic and their enzymatic degradation 
β-lactam antibiotics mediate bactericidal activity by binding irreversibly to penicillin binding 
proteins (PBP) involved in peptidoglycan synthesis and thus inhibit cell wall synthesis. 
Structurally, the β-lactam ring of the antibiotic molecule is essential for the reaction with the 
PBP. β-lactams are composed of four main classes: penicillins, cephalosporins, monobactam, 
and carbapenems that have different spectra of activity. The carbapenem-family includes 
among others the drugs imipenem, meropenem, and ertapenem (160). 
Bacteria produce β-lactamases that hydrolyze the β-lactam ring of the antibiotic, thus 
rendering it inactive. The enzymes are classified according to their mode of hydrolysis into 
four groups proposed by R.P. Ambler (161): Ambler class A, B, C and D and are described 
more in detail in the next section. Penicillinases and cephaloporinases degrade penicillins and 
cephalosporins, respectively. Extended spectrum β-lactamases (ESBL) degrade all β-lactams, 
except carbapenems. Carbapenemases inactivate carbapenems and can also degrade 
penicillins and cephalosporins (162).  
Notably, drugs with the capacity to inhibit β-lactamases have been developed. Inhibitors of β-
lactamases act as a decoy for β-lactamases that will preferentially bind to the inhibitor instead 
of the antibiotic by virtue of a higher affinity. None of the inhibitors available can target all 
the existing β-lactamases. The inhibitors of β-lactamases that are available on the market 
include clavulanic acid, tazobactam and sulbactam (163, 164) and are combined with β-
lactam antibiotics during treatment. 
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1.4.2 Carbapenem resistant Enterobacteriaceae 
Enterobacteriaceae are Gram-negative bacteria that belong to the normal microbiota but can 
cause infections such as cystitis, sepsis and pneumonia. E. coli is a main disease-causing 
agent both in the hospital and in community settings (163), and infections with carbapenem-
resistant bacteria are associated with higher risk of mortality (165). Resistance to antibiotics 
by enzymatic degradation has built up over the years. The treatment of choice of ESBL-
producing Enterobacteriacae is carbapenems (166), and this promoted the development of 
carbapenem resistance. Colistin is a last-resort antibiotic against carbapenem resistant 
Enterobacteriaceae (CRE) but plasmids encoding resistance to colistin has been recently 
described (167), leaving us with limited treatment options against multidrug-resistant (MDR) 
or extensively drug-resistant (XDR) strains. CRE are now ranked as a critical priority for 
research and development in the WHO guidelines (168).  
Carbapenem resistance is often paired with non-enzymatic mechanisms of resistance (165). 
For example, Gram-negative bacteria have an outer membrane that protects them against 
antibiotics. However, hydrophilic antibiotics can still get through the porins present on the 
outer membrane. The loss of porins or the overexpression of efflux pumps, able to transport 
antibiotic outside the bacteria, confers bacterial resistance to antibiotics by impermeability 
(169). Lastly, mutations or modifications in the binding site of the antibiotic constitute yet 
another mechanism of resistance (169). 
Some ESBL enzymes have weak carbapenemase activity and if combined with bacteria 
impermeability mechanisms, they can cause phenotypic carbapenem resistance (163). 
However, this last mechanism constitutes a lower public health threat than carbapenemase-
producing bacteria. Carbapenemases are encoded by plasmids that are highly transmissible by 
horizontal gene transfer between Enterobacteriacae and can be responsible of outbreaks 
(165). 
Carbapenemase enzymes fall into the Ambler class A, B and D (165). The enzymes from 
class A and D contain serine residues in their active sites (160). Amber class A β-lactamases, 
represented mainly by KPC enzymes, are broad and can be inactivated in vitro by the β-
lactamase inhibitor clavulanic acid. Amber class D enzymes differ from A because they also 
cleave oxacillin antibiotic (and thus were named oxacillinase) and comprise OXA-48 family 
enzymes. Amber class D enzymes do not hydrolyze cephalosporins from the second and third 
generations (163). Ambler class B enzymes or metallo-β-lactamases use zinc for hydrolysis 
of the β-lactam ring. They confer a high level of drug resistance to the bacteria when 
combined with membrane impermeability since they hydrolyze all β-lactams except 
monobactam and aztreonam. They are inactivated by metal chelators and not by traditional β-
lactamase inhibitors, such as clavulanic acid. The main class B enzymes are NDM, IMP and 




Carbapenem resistance is a global and concerning threat. E. coli is part of the 
Enterobacteriaceae family and express the riboflavin pathway. It is thus plausible that the 






This thesis work intends to decipher mechanisms of the antimicrobial role of MAIT cells in 
different settings.  
Overall, the aims can be defined as followed.  
Paper I: Investigate the MAIT cell functional response against IgG-opsonized bacteria and in 
vaccination settings.  
Paper II: Explore the cytotoxic mechanisms of MAIT cells against E. coli, including 
carbapenem resistant E. coli.  






For an in-depth description of the methods used, the reader is invited to consult the methods 
section of each paper. A brief summary of the main methods performed is described in this 
chapter. 
3.1 ETHICAL CONSIDERATIONS 
Ethical permits were granted before any studies started.  
For blood and tonsils used in paper I and III, informed written consent was obtained from all 
donors in accordance with study protocols conforming to the Declaration of Helsinki and 
approved by the Regional Ethics Review Board in Stockholm. 
For the serum samples used in paper I, informed written consent was obtained from all 
donors and the study was performed in accordance with the Declaration of Helsinki and 
approved by the Regional Ethics Review Board in Stockholm and by the Swedish Medical 
Product Agency. The study was registered as NCT01847781. 
For blood and nasal tissues used in paper II, informed written consent was obtained from all 
donors in accordance with study protocols conforming to the Declaration of Helsinki and 
approved by the National University of Singapore Institutional Review Board and by the 
Singapore General Hospital Institutional Review Board.  
3.2 SAMPLES COLLECTION 
Blood samples were obtained from healthy donors following the local rules. Peripheral blood 
mononuclear cells (PBMC) were isolated by density gradient centrifugation on Lymphoprep 
and either used fresh for MAIT cell purification (paper I, II, III) or frozen for later use (paper 
II). 
Tonsils were collected from healthy donors undergoing tonsillectomy due to sleeping 
disorder and tonsillar mononuclear cells were obtained as PBMC after a step of mechanical 
dissociation and filtering (paper I). 
Nasopharyngeal samples were obtained from healthy donors undergoing nasal polyp removal 
(paper II). 
3.3 CLINICAL BACTERIAL STRAINS 
3.3.1 Clinical E. coli strains 
E. coli clinical strains used in the paper II are listed in table 1.  
MDR bacteria are resistant to at least one drug in at least three antimicrobial categories. XDR 




Strain Site of 
culture 
Carbapenemase ESBL Efflux 
protein 
mcr-1 Resistance 
EC120 Blood Non-CRE - ND ND N/A 
EC234 Blood Ambler class B + - - MDR 
EC241 Sputum Ambler class A + + - MDR 
EC362 Sore tissue Ambler class A + ND + XDR 
EC385 Blood Ambler class D + - - MDR 
Table 1. E. coli strains list used in paper II. ESBL: extended spectrum β-lactamase, mcr-1: mobilised colistin 
resistance N/A: not application, ND: no data. 
3.3.2 Clinical S. aureus strains 
The clinical S. aureus strains 134, 289, 37, 159 and 160 were used in paper III and were 
previously characterized (171). 
3.4 FUNCTIONAL ASSAYS 
3.4.1 MAIT cell activation assay 
To activate MAIT cells, MR1-expressing APC were required. The THP-1 cell line was used 
for that purpose in paper I and III, while in paper II we used 293T-hMR1 cell (293T stably 
transfected with human MR1 - gift from Ted Hansen), HeLa cells and in some experiments a 
complete PBMC population. APCs were fed with different mildly fixed strains of bacteria, 
according to the project’s need. The microbial dose varied with the project, and incubation 
time usually lasted for 3 hours before adding Vα7.2+ cells at a 2:1 ratio, except for PBMC 
that already contained MAIT cells. Vα7.2+ cells were used as source of MAIT cells and were 
isolated from PBMC by MACS purification as per the manufacturer’s instructions. Cells 
were co-cultured for 24 hours, with the last 6 hours in the presence of monensin and brefeldin 
to assess cytokine production by flow cytometry. This method was previously described by 
Dias et al (98). 
To assess MAIT cell degranulation, CD107a antibody was added at the beginning of the co-
culture. In selected experiments, anti-CD28 was added as a co-stimulatory signal. In some 
experiments, we blocked TCR or cytokine activation using anti-MR1, anti-IL-12 or anti-IL-
18 antibodies.  
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3.4.2 MAIT cell expansion assay performed in paper II 
MAIT cell expansion was performed following two protocols. The first protocol was based 
on isolated MAIT cells from fresh PBMC by MACS-purification using either the 5-OP-RU-
hMR1 tetramer or the Vα7.2 antibody. MAIT cells were then cultured in the presence of IL-
2, IL-7, and CD3/CD2/CD28 polyclonal T cell activator or IL-2 and IL-7 alone for 2 to 15 
days, according to the need.  
The second expansion protocol utilized cryopreserved PBMC. Thawed PBMC were cultured 
in IL-7, IL-2 and stimulated with 5-OP-RU antigen at day 0, 5, and 10. At day 11, live cells 
were separated by density gradient centrifugation on Ficoll. At day 15, MAIT cells were 
checked for purity, and used in functional assays when purity exceeded 70%. Expanded 
MAIT cells used in the different assays were cultured according to this second protocol, 
unless indicated. 
3.4.3 MAIT cell cytotoxic assays used in paper II 
3.4.3.1 Killing assay  
To assess MAIT cell killing of infected cells, HeLa or 293T-hMR1 cells were incubated with 
the appropriate fixed E. coli at the microbial dose of 30 for 3 hours. Expanded MAIT cells 
were then added at an effector to target ratio 5:1 for 24 hours (as described in (82, 98)). 5-OP-
RU-pulsed target cells were used a positive control. CD107a antibody was added at the 
beginning of the assay to assess MAIT cell degranulation over the course of the co-culture. 
Apoptosis of the target cell was assessed with caspase 3 staining and live/dead cell marker. 
To assess MAIT cell killing of cell-associated bacteria, the adherent HeLa cells were infected 
with live E. coli at different microbial doses for 3 hours in antibiotic free media. Infected cells 
were then washed with medium containing 200 µg/mL gentamicin and incubated for 1 hour 
to eliminate extracellular bacteria. The cells were then washed with antibiotic free media 
before adding the expanded MAIT cells at 5:1 ratio for 3 hours. To allow distinction from the 
target cells, MAIT cells were stained with Cell Trace Violet (CTV) dye before addition to the 
culture. For enumeration of bacteria, supernatants were collected and the adherent cells were 
lysed with 0.1% Triton-X for 10 min at RT. To stop the lysis, lysogeny broth (LB) was added 
and the lysates were plated in duplicated on LB plate and incubated for 24 hours at 37°C 
before visual counting. In parallel, a duplicate plate was always run to assess MAIT cell 
degranulation by flow cytometry as described in (117). 
3.4.3.2 Preparation of MAIT cell supernatant 
Supernatant used to assess killing of extracellular bacteria was prepared as follows. 293T-
hMR1 cells were incubated with 2 nM 5-OP-RU in antibiotic free media for 2 hours before 
adding the expanded MAIT cells at 10:1 ratio for 24 hours. Supernatant of the co-culture was 
collected by centrifugation and snap-frozen. The protein content was measured with the 
LEGENDplex human CD8/NK cell panel. 
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3.4.3.3 Killing of extracellular bacteria 
MAIT cell supernatant was incubated with overnight bacterial culture with or without 
carbapenem antibiotics in flat-bottom 96-well plate for 24 hours at 37°C. Live bacteria were 
harvested at different times, diluted in LB broth and plated in triplicate in LB plate and 
incubated for 24 hours at 37°C before enumeration. 
3.5 SPECIAL REAGENTS 
The 5-OP-RU antigen was prepared as described in (172). 
The MR1 tetramer technology was developed jointly by Dr. James McCluskey, Dr. Jamie 
Rossjohn, and Dr. David Fairlie; and the material was produced by the NIH Tetramer Core 
Facility as permitted to be distributed by the University of Melbourne. 
3.6 FLOW CYTOMETRY 
Flow cytometers are fantastic tools developed in the 1960s and are essential for 
immunological discovery. Flow cytometers allow physical and fluorescence measurements 
(known as parameters) of millions of single cells. Because the different measurements are 
done at the same time, it is called multiparameter flow cytometry. Stained cells are loaded 
into the flow cytometer fluidic system and the hydrodynamic focusing allows the cells to be 
aligned in the flow cell. When the cell crosses the center of the focused laser beam, also 
called the interrogation point, information from the excited fluorochrome is collected as 
emitted light. In the Fortessa or Symphony analyzers from BD Bioscience, the different lasers 
are installed sequentially so the cells pass in front of 5 different lasers. The light detectors are 
installed in polygons and routed with optic fiber. The emitted light is detected by the 
detectors that transform the photon signal into an electrical signal (electron). The signal is 
further amplified by the photomultipliers (PMT) and the amplification depends on the voltage 
applied on the PMT. The electrical pulse carries vital information: its height, area and width 
that will be extracted by the electronic hardware and allow the display of the information in a 
plot. The cell itself will scatter light that will be harvested in the forward and side detector. 
Those physical parameters can then be displayed in a plot with the forward-scatter (FSC) and 
side-scatter (SSC) parameters (173, 174). 
The PMT voltage can be changed by the users. Setting optimal PMT voltage is essential to be 
at the sweet spot of the detector and to have the best separation between positive signal and 
background to resolve dim populations. Setting correct PMT voltage gain is a world of its 
own with several guides available for that purpose (175, 176).  
Multiparametric flow cytometry comes with the cost of doing what the field calls 
compensation. A very comprehensive guide about compensation was written by M. Roederer 
(177). Most of the emission spectra of fluorochromes are not sharp peaks, but are spread over 
broad wavelengths, and some of the dyes have overlapping emission spectra. The detectors 
collecting the light have optical filters that are calibrated for a certain wavelength, but it can 
happen that the light collected does not only come from the intended fluorochrome but 
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several, due to spectral overlap. This would lead to wrong results unless we remove unwanted 
signals trough compensation. By acquiring a single fluorochrome at the time, we see the 
spillover of each fluorochrome into all the channels. The spillover value into each detector is 
calculated and used by the compensation algorithm to correct for the spillover (173, 174). 
Fluorescence spillover leads to a reduction of sensitivity in the affected detector. Because the 
detectors have difficulty to count number of photons when several fluorochromes are hitting 
it, this creates spreading errors. This measurement error happens on compensated data. 
Spreading errors make it difficult to separate populations due to the spread of the negative 
population into the positive one, and indicates that the panel needs further optimization (178). 
The maintenance of flow cytometry instruments is essential for good performance (175, 179, 
180). The performance of the instrument should be assessed daily to assure flawless 
performance and collection of high-quality data. At CIM, we rely on the Cytometer Setup and 
Tracking (CS&T) software developed by BD (175). By running CS&T beads composed of 
dim, mid and bright beads, this allows a daily measurement of different parameters including 
coefficient of variation and PMTV that will be compared to reference values. The 
performance can either indicate a pass, a warning, or fail. In case of troubleshooting needed, 





4 RESULTS AND DISCUSSION 
4.1 MAIT CELL RESPONSES TO OPSONIZED BACTERIA 
Opsonization is the process to coat pathogens with either antibodies or complement system 
components to enhance recognition by immune cells. Immunoglobulin G (IgG) antibodies 
binding to Fcγ receptors (FcγRs) trigger different functions: secretion of cytokines and 
chemokines, antibody-dependent cellular cytotoxicity (ADCC), phagocytosis and antigen 
presentation (182, 183). FcγRs, mainly expressed on APCs, are divided into three classes. 
The activating FcγRs are FcγRI (CD64), FcγRIIA/C (CD32A/C), and FcγRIIIA (CD16A). 
Pathogens are much more effectively engulfed by APC when opsonized (182-186) and are 
more efficiently presented to T cells (187, 188). At the start of the study, it was unknown if 
opsonization alters MR1-presentation and modifies MAIT cells responses. This prompted us 
to investigate if MAIT cells respond differently to IgG-opsonized bacteria compared to their 
non-opsonized counterparts. 
4.1.1 MAIT cell functionality increases upon stimulation with IVIg-opsonized 
E. coli 
As a model organism, we used E. coli D21, a common lab strain. Intravenous 
immunoglobulin G (IVIg) was used to opsonize E. coli (IVIg-E. coli). In the presence of 
THP-1 pulsed IVIg-E. coli stimulation, blood MAIT cell functions were increased with a 
superior production of IFNγ, TNF, IL-17A, GzmB and CD107a degranulation compared to 
non-opsonized E. coli (Figure 4A). This was in line with the recent observation of Banki et al 
(189), that MAIT cells increase IFNγ and TNF upon stimulation with IgG-opsonized E. coli. 
Furthermore, our data showed that MAIT cell responses to IVIg-E. coli were highly 
polyfunctional: the percentages of cells expressing GzmB+IFNγ+TNF+ or GzmB+IFNγ+ 
profiles were augmented (Figure 4B). This was reflected in the transcription factor profile 
with an increase in T-bet expression (Figure 4C and D), which is important for the Th1 
phenotype in MAIT cells. The response of MAIT cells to IVIg-E. coli was more MR1-
dependent than to non-opsonized E. coli (paper I, Fig. 1D left and Suppl. Fig. 1F), indicating 
that antigen presentation is probably more efficient in opsonized conditions. 
To test if tissue MAIT cells respond similarly to opsonized pathogens, we used MAIT cells 
from tonsils, a readily accessible lymphoid tissue. MAIT cells from tonsils also increased 
IFNγ, IL-17A, GzmB secretion and CD107a degranulation upon IVIg-E. coli stimulation 
compared to non-opsonized E. coli (paper I, Suppl. Fig. 1 A and B). Of note, the level of IL-
17A production was higher in tonsil than in blood, concordant with the previously observed 
higher IL-17A production in mucosal tissue (51, 57, 110).  
The sensitivity of antigen detection is important during infection, and we therefore 
investigated the dose response of MAIT cells to IVIg-E. coli stimulation. At a suboptimal 
bacterial dose, opsonization enhanced the cytokine production of MAIT cells (paper I, Fig. 
3A and Suppl. Fig. 2A). Furthermore, increased concentration of IVIg amplified this pattern. 
Thus, bacterial IgG opsonization reduces the sensitivity threshold of MAIT cells, allowing 
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detection of lower concentrations of bacteria. The kinetics of MAIT cell responses were also 
faster to stimulation with IVIg-E. coli than to non-opsonized E. coli (paper I, Fig. 3B and 
Suppl. Fig. 2B). 
 
Figure 4. Opsonized bacteria enhance MAIT cell functionality. (A) Frequency of MAIT cells expressing IFNγ, 
TNF, CD107a, GzmB and IL-17A upon stimulation with IVIg-E. coli or non-opsonized E. coli. (B) 
Polyfunctional profile of MAIT cell cytokine production. Histogram plots (C) and combined data (D) of the 
expression of RORγT, T-bet and PLZF in MAIT cells upon stimulation. Adapted from paper I (190). 
4.1.2 FcγR triggering increases MR1 antigen presentation to MAIT cell 
MR1 surface expression on THP-1 cells increased in the presence of IVIg-E. coli (Figure 5A 
and B). As a mirror effect, TCR triggering in MAIT cells also increased upon IVIg-E. coli 
stimulation (paper I, Suppl. Fig. 1C and D), suggesting a more efficient antigen presentation 
to MAIT cells. Therefore, we aimed to understand if triggering of FcγR increases MR1 
antigen presentation. We first blocked binding of IVIg-E. coli to the FcγR, using either Fc 
fragment from human IgG to saturate the FcγR expressed on the THP-1, or by 
deglycosylating the IVIg before opsonizing the bacteria. Indeed, glycosylation is essential to 
bind FcγR (191, 192). By blocking FcγR binding, the upregulation of MR1 surface 
expression in response to IVIg-E. coli was inhibited (Figure 5C), the extent of TCR 
downregulation on MAIT cells was reduced (paper I, Suppl. Fig. 3E) and cytokine response 
was back to the level of the non-opsonized condition (Figure 5D, E and F; paper I, Suppl. Fig. 
3A and E). Taken together, these data demonstrate that FcγR triggering is essential to 




Figure 5. FcγR triggering increases MR1 antigen presentation to MAIT cells. Histogram (A) and combined data 
(B) of MR1 cell surface expression on THP-1 fed with IVIg-E. coli or non-opsonized E. coli for 3 h. (C) MR1 
cell surface expression on THP-1 stimulated with IVIg-E. coli or non-opsonized E. coli in presence of Fc 
fragment for 3 h. (D) IFNγ+CD69+ and TNF+CD69+ expression in MAIT cells stimulated with IVIg-E. coli or 
non-opsonized E. coli with or without Fc fragment for 24 h. Flow cytometry plots (E) and combined data (F) of 
IFNγ+CD69+ and TNF+CD69+ in MAIT cells stimulated with deglycosylated IVIg-E. coli, IVIg-E. coli or non-
opsonized E. coli for 24 h. Adapted from paper I (190). 
To further dissect how FcγR triggering interacts with MR1 ligand loading, we interrogated 
different steps of the antigen presentation pathway using specific chemical inhibitors (Figure 
6). First, we inhibited phagocytosis by using cytochalasin D, an actin polymerization 
inhibitor. Without phagocytosis, there is no bacterial processing and no antigen presentation. 
At steady state, MR1 is retained in the ER and travels to the cell surface only if bound to a 
ligand (38). Exposing THP-1 cells to brefeldin A, an ER egress inhibitor, abrogated MR1 cell 
surface expression in all conditions. MR1 may acquire new antigens during recycling, but for 
a new ligand to be bound, the previous ligand needs to be unloaded. This can happen in an 
acidic compartment since the Schiff base binding, essential for 5-OP-RU binding to MR1, is 
labile in acidic condition (44). Bafilomycin A, an inhibitor of lysosomal acidification, 
partially inhibits MR1 expression after IVIg-E. coli, suggesting that MR1 acquisition of new 
antigen in the endosome may occur in this condition. Finally, the inhibition of Syk using 
R406 inhibitor, that transmits signals from the FcγR, inhibits MR1 cell surface expression. 
Altogether, these findings suggest that phagocytosis, FcγR triggering, MR1 ER egress and 





Figure 6. Increased MR1 antigen presentation is dependent of uptake, ER egress, lysosomal acidification and 
FcγR triggering. MR1 cell surface expression on THP-1 stimulated IVIg-E. coli or non-opsonized E. coli with or 
without chemical inhibitors for 3 h. Adapted from paper I (190). 
4.1.3 Sera from vaccinated individuals boost MAIT cell function 
S. pneumoniae is a Gram-positive pathogen that can colonize the upper respiratory tract, 
especially during childhood. It is an opportunistic pathogen, which can cause mild to severe 
diseases, including pneumonia, sepsis and meningitis (193), particularly as secondary 
infections (194) and in immunodeficient patients (195, 196). S. pneumoniae have many 
virulence factors, the major being the capsule (193). The humoral immune response raises 
antibodies directed against the capsular polysaccharides but also against protein antigens 
(197). Opsonization of S. pneumoniae with IgG allows more efficient processing by 
macrophages (197, 198). In addition, vaccination with the 13-valent S. pneumoniae vaccine 
(Prevnar-13) elicits an antibody response that prevents infection against the serotypes 
included in the vaccine (199-201). The sera from 9 healthy donors, taken before and after 
vaccination with the Prevnar-13 vaccine were characterized in a previous clinical trial for S. 
pneumoniae specific-antibody concentration and opsonophagocytic activity titer (199). We 
pooled the sera of these 9 donors to opsonize the vaccine strain S. pneumoniae 19A, and use 
it to stimulate MAIT cells and assess their functional profile. S. pneumoniae 19A opsonized 
with serum after vaccination elicited higher IFNγ and TNF secretion, and more CD107a 
degranulation in MAIT cells compared to S. pneumoniae 19A opsonized with serum before 
vaccination (Figure 7). The MAIT cell responses to S. pneumoniae 19A were MR1-
dependent, as blocking MR1 with the Ac-6-FP reduced IFNγ and TNF production (paper I, 
Suppl. Fig. 4C). Altogether, these data suggest that the antibodies raised by the vaccination 




Figure 7. Percentage of MAIT cells expressing IFNγ+CD69+, TNF+CD69+, CD107a+, GzmB+ and Vα7.2 
expression after a 24 h stimulation with THP-1 cells pulsed with S. pneumoniae opsonized with sera taken 
before, or after vaccination with the 13-valent pneumococcal vaccine. Adapted from paper I (190). 
4.1.4 Implication for MAIT cells in the vaccine field 
The role of MAIT cell in vaccine-induced immunity is currently unclear. Few published 
studies concerned the administration of the 5-OP-RU antigen as a vaccine. In mice, 
vaccination with the antigen 5-OP-RU combined with TLR9 agonist (123) or IL-23 (128) 
contributes to protection against Legionella longbeachae by increasing MAIT cell numbers in 
the lungs and allowing better bacterial load control. Moreover, the protection occurs earlier 
compared to non-vaccinated mice. However, another study using the combination of 5-OP-
RU + TLR9 agonist as vaccine in the context of MTB infection did not see an improvement 
of bacterial load control (126).   
A few other studies investigated MAIT cells after traditional vaccination. In the context of 
Bacillus Calmette-Guerin (BCG) vaccine administration in humans, MAIT cells were 
activated after in vitro stimulation (138), while they were directly activated in vivo in the case 
of macaques (202). A challenge study with live S. Typhi showed that MAIT cells are 
activated and decreased in the blood of volunteers that developed typhoid fever (Salerno, 
2017). Live attenuated vaccine of F. tularensis in mice induces MAIT cell proliferation and 
cytokine production in the lung (124). Furthermore, MAIT cells perform a helper function by 
secreting GM-CSF that supports monocyte maturation and the subsequent recruitment of 
CD4+ T cells (129). Recent findings by the group of Paul Klenerman in Oxford show that 
MAIT cells are important for optimal immune responses to adenoviral vaccine vectors (203). 
In this context MAIT cells participate as innate viral sensors and amplify the innate response 
to the adenovirus vector with enhanced adaptive CD8+ T cell responses to the vaccine 
encoded antigen. These results open a new avenue in the study of MAIT cells in vaccinology.   
Looking at the humoral side of vaccine immunity, MAIT cells may be mobilized at both sides 
of the response, during the initiation of B cell responses and during the effector phase of 
humoral immunity. Two animal studies show that MAIT cells are able to provide B cell help, 
through the maturation of naïve B cells and the induction of antibody production. The 
supernatant of MAIT cells from Simian immunodeficiency virus (SIV)-vaccinated macaques 
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stimulated with CD3/CD28 increased CD38 and CD69 expression on naïve B cells and was 
able to induce tissue-like memory B cells, which in macaques is the equivalent of plasma 
cells in humans. Furthermore, blood MAIT cell frequency correlated with the presence of 
some specific clones of memory B cells and with the titer of SIV-specific antibodies in 
rectum, suggesting that vaccination against SIV may trigger MAIT cells to help B cells 
maturation and secretion specific antibodies (141). Another study in mice in the context of 
Vibrio cholerae infection showed that the adoptive transfer of MAIT cells into mice lacking 
T cells promote pathogen specific IgA secretion upon challenge (62). Both studies indicated 
that MAIT cells helped initiate B cell responses.  
In our study, we showed that IVIg-E. coli enhanced MAIT cell cytokine and cytotoxic protein 
production (Figure 8). The sensitivity to bacteria was also higher, so that MAIT cell 
responded to IVIg-E. coli at a lower bacterial dose. Furthermore, the kinetics of the response 
was also faster, suggesting that in vivo MAIT cells would respond quicker to opsonized 
microbes. The mechanism relies on activating FcγR. By triggering FcγR, IVIg-E. coli 
increase MR1 antigen presentation and antigen detection, leading to enhancement of MAIT 
cell function. Finally, we showed that the antibodies raised against S. pneumoniae during 
vaccination boosted MAIT cell cytokine production and degranulation. Altogether, we 



















4.2 MAIT CELL CYTOTOXIC RESPONSES OVERCOME CARBAPENEM 
RESISTANCE IN E. COLI  
After investigating MAIT cell responses against opsonized E. coli, we next examined MAIT 
cell-mediated antimicrobial activity against antibiotic-resistant E. coli. We focused our effort 
on CREC, which are highly drug-resistant organisms and constitute a global public health 
threat (163, 168). Due to the highly conserved nature of riboflavin synthesis and the critical 
role of riboflavin for bacterial metabolism, we hypothesized that MAIT cells are able to 
mediate antimicrobial activity even against bacteria that have developed antibiotic resistance. 
4.2.1 Temporal expression of MAIT cell cytolytic proteins regulates bacterial 
load control in vitro  
To assess MAIT cell antimicrobial activity against CREC, we initially developed a MAIT 
cell antimicrobial activity assay against drug-sensitive E. coli using in vitro expanded MAIT 
cells. Resting blood MAIT cells do not express cytolytic molecules, such as Gnly, GzmB, or 
perforin but do express GzmA (paper II, Fig. 1J and (82, 83)). MAIT cells cultured in vitro in 
the presence of 5-OP-RU antigen and the cytokines IL-2 and IL-7 upregulated their cytolytic 
granule content. The culture of cells not only prime MAIT cells for killing infected cells but 
also allowed us to have sufficient cell number to perform the killing assay. After a 15-day 
culture in the aforementioned conditions, nearly all MAIT cells expressed GzmB, GzmA, 
perforin, and Gnly (paper II, Fig. 1J). This increase in cytotoxic molecules reflected their 
killing capacities. Resting MAIT cells were not able to kill HeLa cells infected with the drug-
sensitive E. coli EC120, while in vitro primed MAIT cells degranulated and killed HeLa cells 
(Figure 9A and B). Caspase 3 activation in the target cells was the read-out to identify 
apoptotic cells (Figure 9B). Prolonged cultures of MAIT cells were far more efficient in 
exerting MR1-dependent bacterial load control within the target cells compared to 2 days 
culture (Figure 9C and paper II, Fig. 1E), which coincided with the increased expression of 






Figure 9. Temporal regulation of MAIT cell cytotoxic abilities. MAIT cell degranulation (A), apoptosis (B) and 
bacteria load (C) in HeLa cells after co-culture of EC120-infected HeLa cells with resting MAIT cells or MAIT 
cells after 2 or 15 days of culture. Adapted from paper II (204). 
The killing of bacteria was not simply caused by apoptosis of the target cells (paper II, Fig. 
2L), or disguised by the bacterial release into the extracellular environment (paper II, Fig. 
1F), but by direct MAIT cell killing of the bacterial cells. GzmB, GzmA, perforin, and Gnly 
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were found within the HeLa cells, indicating that the cytotoxic proteins were delivered into 
the infected cells (paper II, Fig. 2A). Furthermore, with a fluorescent GzmB substrate, we 
detected active GzmB in the infected HeLa cells when co-cultured with MAIT cells (paper II, 
Fig. 2H), indicating that GzmB was delivered into the target cells. Lastly, the expression of 
GzmB and Gnly in MAIT cells correlated with the reduction of bacterial viability (paper II, 
Fig. 1D-G). To confirm the cell-associated bacteria killing ability were linked to MAIT cell 
cytotoxic capacity, we blocked the cytolytic machinery using pharmacological inhibitors. 
Inhibiting MAIT cell degranulation with the Ca2+ chelator ethylene glycol tetraacetic acid 
(EGTA) in the presence of Mg2+ abrogated MAIT cells degranulation, caspase 3 activation in 
the target cells, and cell-associated bacterial load control (paper II, Fig. 1J-L). Moreover, 
blocking GzmB with N-acetyl-L-isoleucyl-L-α-glutamyl-N-[(1S)-2-carboxy-1-formylethyl]-
L-threoninamide trifluoroacetate (Ac-IETD-CHO) affected the bacterial load control and 
impaired killing of the target cell, but did not affect MAIT cell degranulation. By contrast, 
blocking GzmA, IFNγ, TNF, and IL-17A did not affect MAIT cell cytotoxic functions (paper 
II, Fig. 1J-L).  
Since bacterial control is a crucial event in mucosal tissues, we tested if tissue MAIT cells 
have similar cytolytic capabilities using nasopharyngeal (NP) samples from healthy 
individuals. NP MAIT cells at steady-state expressed low levels of cytotoxic molecules, 
similar to blood MAIT cells. Culture of the cells in IL-7, IL-2, and 5-OP-RU upregulated 
GzmB, Gnly, perforin, and GzmA at a rate similar to that observed in matched blood MAIT 
cells, but at a somewhat lower magnitude (paper II, Fig. 1K and L). Nevertheless, NP MAIT 
cells were efficient at killing HeLa cells infected with EC120 through cytolytic protein-
dependent pathway (paper II, Fig. 1M). 
Altogether, these data demonstrated that MAIT cells kill infected cells and cell-associated 
bacteria through exocytosis of cytotoxic molecules. Moreover, the antimicrobial properties of 
MAIT cells are maintained in the mucosa. 
4.2.2 Antimicrobial properties of MAIT cells are maintained against 
carbapenem-resistant E. coli (CREC) 
4.2.2.1 MAIT cells are activated by CREC and kill CREC-infected cells 
Next, we assessed if the cytotoxic properties of MAIT cells were maintained against CREC 
clinical isolates. We first confirmed that CREC strains EC234, EC241, EC362 and EC385 
expressed the riboflavin pathway. All the CREC strains grew in a riboflavin-free medium and 
expressed the ribA gene coding for the first enzyme in the riboflavin pathway (paper II, 
Suppl. Fig. 3A-I). Stimulation of the PBMC pool with CREC strains EC234, EC241, EC362, 
and EC385 induced MAIT cell cytokines production and degranulation in an MR1-dependent 
way (paper II, Fig. 3A and B). To determine if MAIT cells can kill CREC-infected cells, we 
co-culture in vitro primed MAIT cells with CREC infected-HeLa cells and assessed caspase 3 
activation and bacterial count in the target cells. MAIT cells retained their MR1-dependent 
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killing capacities against CREC-infected HeLa cells and could also reduce the cell-associated 
bacteria viability, in a TCR-dependent way (Figure 10A and B and paper II, Fig. 3C and D). 
4.2.2.2 Cytolytic proteins produced by MAIT cells damage free-living CREC 
Since MAIT cell cytolytic granule content was found in the surrounding environment (paper 
II, Suppl. Fig. 4A-C), we explored the capacity of MAIT cells to kill extracellular bacteria. 
The CREC strains EC234 and EC362 were incubated in supernatants from the co-culture of 
5-OP-RU-pulsed 293T-hMR1 cells with MAIT cells. Bacterial damage was assessed using 
SYTOX Green, an impermeable nucleic acid dye that will stain bacteria only if there is cell 
membrane damage. In the presence of MAIT cell supernatants, SYTOX Green staining 
increased in the CREC strains, suggesting bacterial membrane damage (Figure 10C and D). 
Control supernatants from 293T-hMR1 cells pulsed with 5-OP-RU did not affect the bacteria. 
Bacterial viability was also reduced in presence of MAIT cells supernatant but not totally 
suppressed (paper II, Fig. 4D). Depletion of Gnly from the supernatants decreased SYTOX 
Green staining, indicating that the supernatants partially lost the antimicrobial properties due 
to Gnly removal (paper II, Suppl. Fig. 6K and L). Gnly is a pore-forming protein targeting the 
bacterial membrane (114), and without Gnly the membrane damage was alleviated. We then 
examined if the cytotoxic molecules could be present inside the CREC. Gnly was found 
inside CREC EC234 and EC362 (paper II, Fig. 5G and H), while GzmB was mostly detected 
in presence of Gnly. Perforin and GzmA were not detected inside supernatant-treated 
bacterial cells (paper II, Suppl. Fig. 7A). Interestingly, GzmB and Gnly were detected mainly 
in SYTOX Green positive EC234 and EC362 bacteria (Figure 10E and F), indicating that 





Figure 10. MAIT cell antimicrobial activity against CREC. Caspase 3 activation (A) and bacterial load (B) in E. 
coli EC241-infected HeLa cells after co-culture with MAIT cells with or without anti-MR1 antibody. 
Representative plot (C) or combined data (D) of E. coli EC234 and EC362 SYTOX Green staining after 
incubation with MAIT cell supernatants or control supernatant. Representative histogram (E) and expression (F) 
of SYTOX Green with GzmB and Gnly in E. coli EC234 and EC362 after incubation with MAIT cells 
supernatants. Adapted from paper II (204). 
Overall, these data demonstrate that MAIT cells were activated by CREC and mediated 
cytotoxicity against CREC-infected HeLa cells by inducing HeLa cell death and by 
controlling cell-associated bacterial loads. Furthermore, the cytolytic proteins Gnly and 
GzmB produced by MAIT cells damaged bacterial membrane and participated in the killing 
of extracellular CREC. 
4.2.3 MAIT cell cytolytic proteins synergize with carbapenem to enhance 
killing of extracellular CREC 
Since MAIT cell granule contents induce bacterial membrane damage, we investigated if 
MAIT cell supernatants were able to enhance carbapenem antibiotic activity against CREC 
strains. To that end, we incubated CREC EC234 and EC362 with MAIT cell supernatants in 
the presence of the carbapenem antibiotics imipenem, ertapenem, or meropenem. Bacterial 
membrane damaged was greatly enhanced by the combination of MAIT cell supernatants and 
carbapenems, compared to the supernatants alone (Figure 11A and B; paper II, Suppl. Fig. 
4I), suggesting that GzmB and Gnly greatly enhanced the antibiotic properties of 








Figure 11. Representative FACS plots (A) and combined data (B) of SYTOX Green staining in E. coli EC234 
and EC362 after incubation with MAIT cell supernatants or control supernatant in presence of imipenem for 2 h. 
Adapted from paper II (204).  
Moreover, the growth of CREC EC234 and EC362 was slowed down or suppressed in the 
presence of MAIT cell supernatants combined with imipenem, at imipenem concentration 
below the minimum inhibitory concentration (MIC) (paper II, Suppl. Fig. 5A and B). Of note, 
EC234 has a MIC to imipenem >32 µg/mL, while the XDR strain EC362 has a MIC to 
imipenem of 8 µg/mL (paper II, Table S1). Thus, MAIT cell supernatants decreased the 
imipenem concentration needed to inhibit the growth of those strains. To further characterize 
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this effect, we performed a kinetics study to assess bacterial killing by MAIT cell 
supernatants in combination with imipenem over time. Over the course of 24 hours, the effect 
of MAIT cell supernatant with titrated amounts of imipenem was assessed on the bacterial 
viability of CREC EC234 and EC362 strains. MAIT cell supernatants combined with 
imipenem kill the bacteria at an imipenem concentration below the MICs of those strains 
(paper II, Fig. 4G and H). Interestingly, the amount of GzmB and Gnly present in the MAIT 
cell supernatants were higher in the donors that abrogated bacterial growth (paper II, Fig. 5A 
and B). Moreover, the amount of GzmB and Gnly in the supernatants correlated with the 
inhibition of bacterial growth (paper II, Fig. 5C-F). No difference was noted in perforin and 
GzmA levels (paper II, Fig. 5A and B). It is also notable to highlight that in some 
experiments, the CREC strains regrew in the presence of combined imipenem and MAIT cell 
supernatants, probably due to the finite amounts of cytolytic proteins in the MAIT cell 
supernatants in these cultures. 
Altogether, these results suggest that MAIT cell cytolytic proteins, particularly Gnly and 
GzmB synergize with carbapenem to enhance and restore the bactericidal activity of 
carbapenems. 
4.2.4 Conclusions 
In this paper, we explored the mechanism underlying MAIT cell antimicrobial cytotoxicity. 
First, we showed that MAIT cells’ direct killing of cell-associated bacteria occured in an 
MR1-dependent fashion. It is interesting to note that these antimicrobial properties are 
temporally regulated since resting MAIT cells do not have killing capacities. Then, we 
confirmed that these antimicrobial properties extended to CREC. The cytolytic proteins 
produced by MAIT cells were present in the surrounding environment and the secreted 
molecules damaged the membrane of free-living bacteria, hence reducing viability. These 
cytolytic proteins also increased the membrane permeability of CREC strains, hence restoring 
the bactericidal effect of carbapenem antibiotics. This effect was primarily mediated by 
GzmB and Gnly. Gnly is an antimicrobial protein that forms pores on bacterial membrane 
(114). GzmB exerts important antimicrobial functions by cleaving vital proteins and 
antioxidant defense enzymes that ultimately lead to bacterial cell death (113). Gnly and 
GzmB were both detected in the damaged bacteria incubated in MAIT cell supernatants, but 
GzmB was only detected in the presence of Gnly, suggesting that Gnly is needed to allow 
GzmB access into the bacterial cells. The addition of carbapenems further exacerbated CREC 
bacterial damage, suggesting the restoration of carbapenems bactericidal activity. Enhanced 
penetration of carbapenems into the bacteria was a likely explanation of increased bacterial 
death following co-incubation with MAIT cell supernatants, and this may be due to the 
increased membrane damage caused primarily by Gnly, and to a lesser extent by GzmB. 
Thus, MAIT cell cytolytic proteins may overcome the impermeability mechanism of drug 
resistance. Overall, these data highlight the important antimicrobial effector functions 




4.3 S. AUREUS EVADES MAIT CELL RECOGNITION WITH THE HELP OF 
LUKED TOXIN 
Finally, we explored if microbes may directly target MAIT cells to avoid recognition and 
circumvent the rapid immune response by these cells. Mechanisms of evasion from MAIT 
cell recognition have been proposed in two studies, but both are related to the MR1 antigen 
presentation pathway. The study by Preciado-Llanes et al (132) showed that modification of 
the ribB gene encoding the enzyme involved in the riboflavin secretion pathway in bacteria 
can block MAIT cell activation. Another study demonstrated impairment of the MR1 antigen 
presentation due to viral infection (205). To assess the existence of other immune evasion 
mechanisms, we switched bacterial model and used S. aureus, for the reasons described 
below. 
S. aureus is a gram-positive opportunistic pathogen that colonizes human skin and nose 
(206). The combined events of barrier breach and secretion of virulence factors can lead to 
pathogenesis and serious diseases such as sepsis, endocarditis, and pneumonia (207-209). 
Virulence factors secreted by S. aureus are key in the pathogenesis and carry redundant 
functions. They are composed of superantigens, cytolytic peptides, and pore-forming toxins. 
The S. aureus superantigen staphylococcal enterotoxin B (SEB) activates MAIT cells and 
renders them anergic to further bacterial stimulation (210). The pore-forming toxin 
leukotoxin ED (LukED) is part of the leukocidin family and is composed of two subunits: 
LukE and LukD. LukE first binds to the receptor before recruiting LukD. Then, the complex 
oligomerizes and inserts into the cell membrane to create a pore, ultimately leading to 
osmolysis (211). LukED binds to several chemokine receptors, including CCR5, CXCR1, 
and CXCR2 (212, 213) and to the duffy antigen receptor for chemokines (DARC) (214, 215). 
These receptors are widely expressed on immune cells such as T cells, NK cells, DC, and 
epithelial cells; therefore, LukED protects S. aureus from numerous types of effector cells. 
LukED is an important virulence factor for disease pathogenesis and mortality of the host 
(212-215). 
From the literature, we know that S. aureus activates MAIT cells (27, 55). MAIT cells 
increase in blood and tonsils during S. aureus tonsillitis (216), but decrease in blood during S. 
aureus bacteremia (217). Since MAIT cells express high levels of CCR5, we were interested 
to investigate if LukED can also target MAIT cells. 
4.3.1 LukED wipes out MAIT cells from a mixed culture 
To investigate the effects of LukED on human MAIT cells, we incubated PBMC with 
recombinant LukED toxin and assessed the alterations of the MAIT cell population using 
flow cytometry. We first used the uniform manifold approximation and projection (UMAP) 
analysis (218), an unsupervised approach to analyze effects on the total lymphocyte 
population (paper III, Fig. 1A and B). In the LukED-treated conditions, the disappearance of 
the population marked by the projection of the 5-OP-RU-hMR1 tetramer staining was 
striking and suggested that LukED depletes the MAIT cell population. The effect of LukED 
on depleting MAIT cells was confirmed by traditional gating, and was almost complete in 
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absolute count or when calculated as percentage out of T cells (Figure 12A). In contrast, 
CCR5+ conventional non-MAIT T cells were not affected to the same extent as MAIT cells, 
in line with the lower CCR5 expression on CCR5+ conventional T cells compared to MAIT 
cells (Figure 12B and C and paper III, Suppl. Fig. 1D). The MAIT cell population was 
rescued by the addition of Maraviroc (MVC) to the culture, a CCR5 antagonist used in HIV 
therapy (paper III, Fig. 2A). The protective effect of MVC was weaker for the CCR5+ 
conventional T cells (paper III, Fig. 2C). It is interesting to note that LukED also targets 
effector memory T cells (TEM), terminally differentiated effector memory CD45RA+ T cells 
(TEMRA), and CD8+CD56+ conventional T cells through CCR5 or CXCR1, although the 
depletion of these subsets was less pronounced than MAIT cells (paper III, Fig. 1J-L and 
Suppl. Fig. 1H-L). 
 
Figure 12. MAIT cells are more sensitive to LukED than CCR5+ conventional T cells. (A) Representative flow 
cytometry plots and combined data of the percentage and absolute count of MAIT cells upon LukED exposure. 
(B) Depletion rate of MAIT cells versus CCR5+ conventional T cells. (C) Representative flow cytometry plot of 
CCR5 expression in MAIT cells and CCR5+ conventional T cells. 
LukED-mediated depletion of MAIT and CCR5+ conventional T cells occurred in a dose-
dependent manner. However, MAIT cells were more sensitive than CCR5+ conventional T 
cells, since the dose needed to kill half of the population (50% of minimum inhibitory 
concentration or IC50) was lower for MAIT cells (paper III, Fig. 2D). The length of exposure 
to the toxin did not have a major impact on toxicity, suggesting that the effect is rapid and 
that the toxin dose is the key paramater for LukED cytotoxicity (paper III, Fig. 2E).  
To further confirm that LukED targets MAIT cells, we incubated PBMC with the 
supernatants of cultures of clinical strains that have been previously characterized for the 
absence or presence of LukED secretion (171). In presence of the supernatant from LukED-
secreting strains, the percentage of MAIT cells declined while MAIT cells population 
exposed to LukED-free supernatant remained unchanged (paper III, Fig. 1M). Overall, these 
data demonstrate that LukED preferentially targets and depletes MAIT cells. 
4.3.2 IL-12 and IL-18 activation may prevent LukED killing of MAIT cells 
MAIT cells can be activated by stimulation with cytokines produced by myeloid cells in the 
innate response, such as IL-18 and IL-12. We therefore investigated how this mode of 
activation may impact the sensitivity of MAIT cells to LukED. PBMC were pre-stimulated 
with IL-12 and IL-8 for 20 hours before adding the recombinant LukED toxin for the last 2 
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hours of the assay. Interestingly, the pre-stimulation with cytokines partially protected MAIT 
cells from LukED; probably via the lowering of CCR5 levels on MAIT cells (paper III, Fig. 
3A-C). 
4.3.3 Sub-lethal LukED doses do not affect MAIT cell responses 
Next, we explored if sub-lethal doses of LukED could impair MAIT cell activation, possibly 
due to signaling defects. MAIT cells were pre-incubated with sub-lethal doses of LukED 
before the addition of THP-1 cells pulsed with mildly fixed S. aureus strains either expressing 
LukED or not. The MAIT cell cytokine expression in response to stimulation was similar 
with or without sub-lethal LukED pre-treatment, irrespective of the bacterial strain (paper III, 
Fig. 3D and E). Altogether, these observations support the notion that that exposure to 
LukED levels below the toxic dose does not impair MAIT cell activation. 
4.3.4 Can MAIT cells mediate antimicrobial function against S. aureus 
infected cells? 
Since S. aureus can activate MAIT cells, we next aimed to investigate if MAIT cell could kill 
S. aureus infected cells and control bacterial loads. We used the protocol previously 
developed in paper II for that purpose. In this assay, gentamicin, an aminoglycoside 
antibiotic, was used to eliminate the remaining extracellular bacteria. Unfortunately, the S. 
aureus strains used were methicillin resistant S. aureus (MRSA) (β-lactam family) and 
resistant also to aminoglycosides, and thus no antibiotic from those classes could be used in 
the assay. We explored other options, but the choice was limited, as we needed a hydrophilic 
antibiotic that stay outside the cells. We turned our attention to the lysostaphin enzyme that 
cleaves glycine in the peptidoglycan layer and lyse the bacteria. Despite that lysostaphin 
should theoretically stay outside the cells (219), it unexpectedly also killed intracellular 
bacteria in our assay. Thus, we unfortunately had to abandon this experimental approach. 
4.3.5 LukED targets mature NK cells 
In the UMAP plot, the area corresponding to the CD56 projection was altered upon LukED 
exposure. This population corresponds to NK cells, and this inspired us to explore more in 
detail this cell type (paper III, Fig. 1A and B). Previously, it was described that LukED 
targets NK cells in CXCR1-dependent manner (213), but the different NK cell subsets were 
not investigated. NK cells are going through different stages of maturation and those can be 
identified using combinations of markers. Upon maturation, NK cells downregulate CD56, 
going from a CD56bright to CD56dim phenotype. Furthermore, mature cytotoxic NK cells gain 
KIR and CD57, and downregulate NKG2A. The FcγRIIIA receptor (CD16) is mainly 
expressed on CD56dim NK cells (220). NK cells may be important for immune control of S. 
aureus infection in vivo (221). Here, we studied NK cells in the same experimental setup as 
MAIT cells: PBMC were incubated in the presence of LukED toxin, and flow cytometry was 
subsequently used to evaluate the effect on NK cells.  
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Our data indicates that LukED depleted NK cells, however the depletion was not complete 
and CD56dim NK cells were particularly vulnerable while CD56bright NK cells were less so 
(paper III, Fig. 4A and B). This was probably due to the higher expression of CXCR1 and 
CXCR2 in CD56dim NK cells (paper III, Fig. 4C and D). Within the CD56dim NK cell 
population, NK cells expressing CD16, CD57, KIRD2L1, perforin or co-expressing CD57 
and KIRD2L1 were more severely depleted (paper III, Fig. 4E and F). This phenotype 
corresponds to the more mature and cytotoxic NK cells. Thus, the LukED toxin targets 
mature effector NK cells. 
4.3.6 Conclusions 
S. aureus infections are widespread in hospital and community settings and are often 
methicillin resistant (MRSA). MRSA are becoming more and more resistant to antibiotics, 
thus reducing treatment options. Moreover, MRSA is responsible for numerous deaths (208, 
222). An effective vaccine would help protect against infections, but vaccine design against 
S. aureus has been difficult due to the redundancy of the multiple virulence factors and lack 
of appropriate animal models (223). Indeed, the toxins do not act the same way in different 
species (224). Mobilization of MAIT cells by vaccination could be attractive due to their 
secretion of IL-17 and IL-22, and their localization in blood and skin, the sites of S. aureus 
infection (223).  
In this paper, we explore how the toxin LukED affects MAIT cells in comparison to 
conventional T cells. We found that MAIT cells are hypersensitive to LukED. However, 
MAIT cells were rescued with the CCR5 antagonist MVC. Within the T cell pool, MAIT 
cells are the most sensitive T cell subset: CCR5+ and CD8+CD56+ conventional T cells, 
TEM, TEMRA cell were not as severely affected. Some of those conventional T cells may be 
part of the Th17 immunity, which is important in the defense against S. aureus. Indeed, 
primary immunodeficiency patients lacking Th17 cells due to genetic mutations are more 
susceptible to S. aureus (225). In this study we also unveil that the most mature and cytotoxic 
NK cell subsets are targeted and depleted by LukED.  
MAIT cell TCR-dependent functions were maintained in presence of sub-lethal levels of 
LukED, indicating that MAIT cells may mediate effective immune defense when the bacteria 
do not produce high level of toxins. Interestingly, pre-activation with IL-12 and IL-18 
protects MAIT cells against LukED probably as a consequence of the downregulation of 
CCR5 in response to stimulation. Antibody-based therapies directed against S. aureus toxins 
are in development to fight against S. aureus infection (226-228). This strategy has several 
advantages, including the protection and possible reconstitution of the pool of cells 
responsible for antibacterial effector functions. Given the fact that MAIT cells are particularly 






5 CONCLUDING REMARKS AND PERSPECTIVE 
MAIT cells were first described 18 years ago (67) and the knowledge gathered in the last 
decade has considerably strengthened the field. MAIT cells are primarily antibacterial 
immune cells, due to the recognition of bacterial antigen but also act as innate sensors of viral 
infection through their cytokine-dependent activation mode. Thus, MAIT cells are broadly 
involved in immunity against infectious disease. Despite the knowledge we have about their 
cytokine response profile and cytolytic protein release, their functional role is not completely 
resolved yet. In this thesis work, we investigated the function of MAIT cells in different 
disease settings. 
The MAIT cell response to bacteria changes if the bacteria are opsonized by IgG (paper I): 
their functional response is stronger and more polyfunctional. MAIT cells respond to lower 
bacterial dose if the bacteria are opsonized, showing increased sensitivity. Furthermore, 
MAIT cells respond faster to opsonized bacteria. The change in functional response is linked 
to FcγR triggering on APCs by the IgG-opsonized bacteria, which leads to increased MR1 
antigen presentation. The relevance of the boost of functionality was validated using 
S. pneumoniae specific-IgG raised during vaccination. After vaccination with Prevnar-13 
(vaccine containing 13 different strains of S. pneumoniae), the sera of vaccinated individuals 
had increased serotype specific antibodies (199). Using pooled sera taken before and after 
vaccination, the vaccine strain S. pneumoniae 19A was opsonized and used to stimulate 
MAIT cells. The MAIT cell response to S. pneumoniae opsonized with serum after 
vaccination displayed increased levels of IFNγ, TNF, and CD107a (degranulation) compared 
to S. pneumoniae opsonized with sera sampled before vaccination. Overall, these findings 
indicate that MAIT cells may constitute an effector arm of humoral immunity, more 
efficiently targeting bacteria that are also targeted by antibodies. One limitation of this study 
is that we did not have paired blood and serum from the S. pneumoniae vaccinated 
individuals. It would be interesting to repeat this experiment using such paired blood and 
serum samples. Since Prevnar-13 is a polysaccharide vaccine, it would be interesting to 
extend the study to a live attenuated vaccine such as BCG or the S. Typhi vaccine (Ty21a). 
Salerno et al. (102) assessed the phenotype of human MAIT cells for a month after S. Typhi 
challenge. MAIT cells declined in blood and were more activated in individuals that 
developed typhoid fever compared to those who did not develop disease. No ex vivo 
stimulation was performed in this study. Since Salmonella IgG-specific antibodies are 
important for increased phagocytosis during secondary challenge (229), it would be 
interesting to investigate the MAIT cell response in this context. Furthermore, MAIT cells 
probably have B cell helper function (62, 141, 230), and it could be interesting to investigate 
if B cell antibody production in the vaccinated individuals correlates with MAIT cell 
activation and possible migration to tissue.  
Apart from B cell help, MAIT cells indirectly orchestrate other downstream antimicrobial 
responses through cytokine release (116). MAIT cells also have direct cytotoxic ability and 
kill bacterially infected cells (83, 103). We showed in paper II that MAIT cell cytotoxicity is 
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active also against cell-associated bacteria, including CREC, and is mediated by cytolytic 
proteins GzmB, perforin, and Gnly. The control of the cell-associated bacterial load by MAIT 
cells was dependent on the timing. MAIT cells seemed to need extended stimulation with IL-
2, IL-7 cytokines to upregulate Gnly. It would be very interesting to know if this temporal 
regulation of MAIT cell killing ability also occurs in vivo. For instance, this could be done 
after 5-OP-RU vaccination in mice with transgenic expression of Gnly (114, 115) since 
rodents are devoid of Gnly. If MAIT cells need a long priming to become cytolytic against 
bacteria, this leaves a long time for the bacteria to cause disease. The cytotoxic proteins 
GzmB and Gnly released by MAIT cells in the surrounding environment damaged the 
membrane of free-living CREC. Interestingly, the addition of carbapenem to this 
environment enhanced the bactericidal effect of MAIT cells in vitro, showing that 
carbapenem synergizes with GzmB and Gnly. We speculated that the increased membrane 
permeability caused by GzmB and Gnly allow the penetration of carbapenem inside the 
bacteria, thus overcoming the impermeability mechanism of antibiotic resistance. To 
demonstrate that carbapenems penetrate the intracellular bacteria in the presence of GzmB 
and Gnly, one may use a fluorescently labelled carbapenem antibiotic (231) that could be 
detected by flow cytometry. It would also be interesting to test if MAIT cells could disarm 
other mechanisms of resistance, such as β-lactamases. Another aspect to test is if MAIT cell 
cytolytic ability extends to other resistant microorganisms. Yet another facet to investigate is 
the possible development of bacterial resistance to GzmB or Gnly. Indeed, mechanisms of 
evasion of MAIT cell recognition were recently shown to exist (132). 
Along these lines, we have investigated further the ability of microbes to escape MAIT cell 
recognition. Some S. aureus strains produce SEB that render MAIT cells anergic to further 
stimulation (210). S. aureus secrete other virulence factors, including the pore-forming toxin 
LukED. In paper III, we found that MAIT cells are extremely sensitive to the LukED toxin. 
LukED also partially depleted TEM, TEMRA, and CD56dim NK cells but to a lower extent 
than MAIT cells, indicating that within the T cell pool MAIT cells are the most LukED-
sensitive population. One may wonder if LukED is one of the causes of MAIT cell depletion 
during S. aureus bacteremia (217). Furthermore, we observed that clinical isolates known to 
secrete LukED depleted MAIT cells in vitro. Given the fact that S. aureus secrete many 
virulence factors, it would be interesting to use congenic strains lacking LukED to ascertain 
that the depletion is LukED-dependent. Unfortunately, this modification is very difficult to 
engineer in clinical bacterial strains and we were not able to pursue this idea for this study. It 
is also unknown what concentration of LukED is secreted at the site of infection. We showed 
that a low dose of toxin does not affect MAIT cell activation in response to antigen. On the 
other hand, IL-12 and IL-18 stimulation seems to partially protect MAIT cells from LukED, 
probably due to CCR5 downregulation. It would be interesting to determine the CCR5 
expression on MAIT cells in situ during S. aureus infection, and if the downregulation 
protects MAIT cells in vivo. From the literature, we know that CCR5 expression is increased 
in blood MAIT cells during acute HIV infection (155), while it is decreased in chronic HCV 
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(232). In tissue, CCR5 was found to be expressed on healthy and diseased liver MAIT cells 
(108), and increased on peritoneal MAIT cells in decompensated liver cirrhosis (233). 
MAIT cells are present in many tissues, and their functions may differ between locations. In 
mucosal tissues, MAIT cells seem to lean towards a more pronounced Th17 profile. At least 
in the nasopharynx, the MAIT cell cytolytic functions seem to be similar to blood. Many 
aspects remain to be unveiled, in particular if tissue localization directs the functionality. If 
MAIT cells traffic between tissues, do the functions adjust to the local environment? It was 
recently found that MAIT cells can have tissue repair functions, but it is also possible that 
some functions are yet to be uncovered. For instance, MAIT cells seem to have B cell helper 
function. To what extent is that compatible or competitive with Tfh cells? MAIT cells also 
produce IL-10 under some circumstances. Does this mean they could perform regulatory 
functions? Studies of human tissue immunology is very challenging, but the field is finding 







Without the caring help from many people, this journey wouldn’t have been possible. 
First to my main supervisor, Johan Sandberg, I’m very grateful to have experience the PhD 
travel in your group. Thank you for your trust in accepting me as PhD student despite my 
broken English. Thank you for opening the MAIT cell world to me, and for allowing me to 
dig freely into it; it has been an invaluable and fascinating experience that pushes me to grow 
in many aspects. I’m very much obliged to that. Thank you for your patience and for always 
being here when I got lost on the road. Finally, thank you for taking the time to review 
written productions; I hope I could learn from your excellent writing skills.  
To my co-supervisor, Edwin Leeansyah, thank you for hosting me in Singapore, this 
experience was one my PhD highlights! Thank you for instilling in me meticulous practices: I 
learnt from you not to forget controls, to ask more rigorous questions and your multiple and 
unceasing questions sparks my scientific journey. Your curiosity is truly inspiring. Best of 
luck for your new journey as group leader! 
Thank you to my other co-supervisor Peter Bergman, for your input, your regular check-ups 
and your availability. I’m very grateful that you granted us access to the precious serum 
samples. 
Thank you to all the co-authors and collaborators. In particular Wan-Rong and Yaaseen for 
their precious help in Singapore. But also to Jenny Mjösberg for letting us access to tonsil 
samples, Andrea Kwa for sharing the clinical E. coli strains, and Anna Norrby-Teglund for 
the S. aureus isolates. 
Without the blood donors, none of these works would have been possible, thank you and 
keep giving blood! 
Merci à Clément Mettling, mon mentor, d’être toujours présent depuis mon passage en 
master à l’IGH. C’est toujours un plaisir de discuter sciences, films, course ou perspective de 
carrière. Merci d’être venu en visite!  
Thank you to the past and present members of the Sandberg lab with whom I shared all these 
years. Joana, for teaching me everything in the lab and for following my baby steps during 
the first months, without your caring help it would have been much harder! David, for always 
baking for group meetings and for your flow tips. Michal, thanks for your funny puns in the 
lab. Kerri, it was always a pleasure when you came to Stockholm, it was always too short. 
Robin, thanks for your help for the CD8-DN paper. JB, thank you for helping me with 
experiments, for always being calm, be an immense resource for questions and for being a 
bio-informatician wizard. Special thanks to Tiphaine, it is really fun to share the office with 
you and to discuss about data and the world. Our discussions teach me more about scientific 
concepts. Johanna, thank you for adding some art in the lab. Louisa, it was really great to 
 
46 
have you in the lab. Tobias, thanks for bringing your enthusiasm to the group. Thank you all 
for all the fun in conferences.  
Thank you to the Lin-Fa Wang lab members in Singapore for hosting me during a couple of 
months. You have all be welcoming, kind and lovely. Geraldine, Xiao Fang, Catherine, 
Pritisha, Randy, Yaaseen, Wanny, Brian, Chee-Wah, Charles, Shermaine thank you for 
the scientific discussion, all the fun in the lab, the lunches at the hawker center or around 
Singapore. I have tons of fond memories of my stay. Thanks to Alfonso from the Bertoletti 
lab, I enjoyed those little chat while waiting for the blood cone. 
It is stimulating to share group meetings with Marcus Buggert group. 
I’m very thankful to Jakob Michaelsson to have accepted me in the FACS team. I learn so 
much from it! I will miss taking care of the Fortessas. To the past and current FACS-team 
members: Aline P., Themis, Laura H. and Elza, I enjoyed taking care of the machine at 
your side and I learnt something from each of you. Thanks to Marion that recently joined the 
team. Sideway, I will also thanks Mario Roederer, flow cytometry expert for his great 
publications and for always reminding me of the homonymous French champagne. 
Thank you to Margit, Lena R. and Elizabeth and past member Annette for keeping CIM 
running smoothly. 
Thank to all the past and present CIMers to make it great fun to come to work: Aline v.A., 
Angelica, Anna R, André, Andrea, Arlisa, Christine, Carles, Ebba, Egle, Emma, Ginny, 
Jagadees, Isabel D.L., Isabel M., Kim, Kimia, Lorentz, Madga L., Madga M., Marina, 
Marianne, Marta B., Martha M., Martin I., Mily, Nicole, Nikolai, Olga, Puran, Quirin, 
Renata, Sebastian, Srikanth, Sofia, Tea, Tyler, Vicky. Thank you for all the 
discussions/company in the lab, offices, at lunch or during afterwork. I’m happy and grateful 
to have been part of such international and fantastic place.  
Martin C., merci pour toutes nos discussions hétéroclites et ce dès mon interview! Ben, 
merci pour partager ta musique dans le labo rouge! Otto, thanks for soothing my time in the 
big lab at old CIM with interesting chats. Tak, arigato gozaimasu four your kind help each 
time I needed it and for all the Japanese sweets. Sam, it was really great to have you around, 
thanks for all the fantastic dinners. Alvaro, thanks for being such a cool cooking-buddy and 
teaching us your family recipe (and for you help at organizing CIM pub with JB). Gao and 
Imran, you two form an incredible duo! It was real fun to share all these lunches together.  
Thank you to family and friends for life outside the lab, keeping in touch despite the distance, 
and for your support all theses years. 
Merci à mes parents pour votre soutien inconditionel toutes ces années, votre compréhension 
et pour votre présence malgré la distance. Mes deux frères Hervé et Vincent et leur petite 
famille Dorothée, Tiffaine et Chimeg, Ananda et Indira, merci de votre soutien et pour 
tous ces beaux moments passés ensemble à Stockholm ou en France. 
 
 47 
Finally, to my partner Philip. Without you, I would have never moved to Sweden and do this 
fantastic PhD journey. Thank you for listening to my failed experiments, my complaints, and 
offering in return invaluable advices. Your support has been endless over the years. Your 







1. Gourbal B, Pinaud S, Beckers GJM, Van Der Meer JWM, Conrath U, and Netea MG. 
Innate immune memory: An evolutionary perspective. Immunological Reviews. 
2018;283(1):21-40. 
2. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, and Charpentier E. A 
programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. 
Science. 2012;337(6096):816-21. 
3. Ramirez-Prado JS, Abulfaraj AA, Rayapuram N, Benhamed M, and Hirt H. Plant 
Immunity: From Signaling to Epigenetic Control of Defense. Trends in plant science. 
2018;23(9):833-44. 
4. Parisi K, Shafee TMA, Quimbar P, van der Weerden NL, Bleackley MR, and 
Anderson MA. The evolution, function and mechanisms of action for plant defensins. 
Seminars in cell & developmental biology. 2019;88(107-18. 
5. Uehling J, Deveau A, and Paoletti M. Do fungi have an innate immune response? An 
NLR-based comparison to plant and animal immune systems. PLoS Pathog. 
2017;13(10):e1006578. 
6. Little TJ, Hultmark D, and Read AF. Invertebrate immunity and the limits of 
mechanistic immunology. Nature Immunology. 2005;6(7):651-4. 
7. Netea MG, Schlitzer A, Placek K, Joosten LAB, and Schultze JL. Innate and 
Adaptive Immune Memory: an Evolutionary Continuum in the Host’s Response to 
Pathogens. Cell Host & Microbe. 2019;25(1):13-26. 
8. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, and Hoffmann JA. The dorsoventral 
regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in 
Drosophila adults. Cell. 1996;86(6):973-83. 
9. Ramon M. Rodriguez AL-VaCL-L. In: Lopez-Larrea C ed. Sensing in Nature. 2012. 
10. Cooper MD, and Alder MN. The Evolution of Adaptive Immune Systems. Cell. 
2006;124(4):815-22. 
11. Kolaczkowska E, and Kubes P. Neutrophil recruitment and function in health and 
inflammation. Nature Reviews Immunology. 2013;13(3):159-75. 
12. Guilliams M, Mildner A, and Yona S. Developmental and Functional Heterogeneity 
of Monocytes. Immunity. 2018;49(4):595-613. 
13. Colonna M. Innate Lymphoid Cells: Diversity, Plasticity, and Unique Functions in 
Immunity. Immunity. 2018;48(6):1104-17. 
14. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama 
WM, and Ugolini S. Innate or adaptive immunity? The example of natural killer cells. 
Science. 2011;331(6013):44-9. 
15. Janssen BJC, Huizinga EG, Raaijmakers HCA, Roos A, Daha MR, Nilsson-Ekdahl 
K, Nilsson B, and Gros P. Structures of complement component C3 provide insights 
into the function and evolution of immunity. Nature. 2005;437(7058):505-11. 
16. Kumar BV, Connors TJ, and Farber DL. Human T Cell Development, Localization, 
and Function throughout Life. Immunity. 2018;48(2):202-13. 
 
50 
17. Cyster JG, and Allen CDC. B Cell Responses: Cell Interaction Dynamics and 
Decisions. Cell. 2019;177(3):524-40. 
18. Godfrey DI, Uldrich AP, McCluskey J, Rossjohn J, and Moody BD. The burgeoning 
family of unconventional T cells. Nature immunology. 2015;16(11):1114-23. 
19. Gherardin NA, Keller AN, Woolley RE, Le Nours J, Ritchie DS, Neeson PJ, 
Birkinshaw RW, Eckle SBG, Waddington JN, Liu L, et al. Diversity of T Cells 
Restricted by the MHC Class I-Related Molecule MR1 Facilitates Differential 
Antigen Recognition. Immunity. 2016;44(1):32-45. 
20. Godfrey DI, Koay H-F, McCluskey J, and Gherardin NA. The biology and functional 
importance of MAIT cells. Nature Immunology. 2019;20(9):1110-28. 
21. Steven Porcelli CEY, Michael B. Brenner, Steven P. Balk. Analysis of T Cell Antigen 
Receptor (TCR) Expression by Human Peripheral Blood CD4-8- a/b T Cells 
demonstrated preferential use of sevral Vb Genes and an invariant TCR a chain. J Exp 
Med. 1993;178(1-16. 
22. Tilloy F, Treiner E, Park S-H, Garcia C, Lemonnier F, de la Salle H, Bendelac A, 
Bonneville M, and Lantz O. An Invariant T Cell Receptor α Chain Defines a Novel 
TAP-independent Major Histocompatibility Complex Class Ib–restricted α/β T Cell 
Subpopulation in Mammals. The Journal of Experimental Medicine. 
1999;189(12):1907-21. 
23. Souter MNT, and Eckle SBG. Biased MAIT TCR Usage Poised for Limited Antigen 
Diversity? Frontiers in Immunology. 2020;11( 
24. Eckle SB, Birkinshaw RW, Kostenko L, Corbett AJ, McWilliam HE, Reantragoon R, 
Chen Z, Gherardin NA, Beddoe T, Liu L, et al. A molecular basis underpinning the T 
cell receptor heterogeneity of mucosal-associated invariant T cells. J Exp Med. 
2014;211(8):1585-600. 
25. Mondot S, Boudinot P, and Lantz O. MAIT, MR1, microbes and riboflavin: a 
paradigm for the co-evolution of invariant TCRs and restricting MHCI-like 
molecules? Immunogenetics. 2016;68(8):537-48. 
26. Chen Z, Wang H, D'Souza C, Sun S, Kostenko L, Eckle SBG, Meehan BS, Jackson 
DC, Strugnell RA, Cao H, et al. Mucosal-associated invariant T-cell activation and 
accumulation after in vivo infection depends on microbial riboflavin synthesis and co-
stimulatory signals. Mucosal Immunology. 2016. 
27. Le Bourhis L, Martin E, Peguillet I, Guihot A, Froux N, Core M, Levy E, Dusseaux 
M, Meyssonnier V, Premel V, et al. Antimicrobial activity of mucosal-associated 
invariant T cells. Nat Immunol. 2010;11(8):701-8. 
28. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, Bhati M, Chen Z, 
Kostenko L, Reantragoon R, et al. MR1 presents microbial vitamin B metabolites to 
MAIT cells. Nature. 2012;491(7426):717-23. 
29. Corbett AJ, Eckle SBG, Birkinshaw RW, Liu L, Patel O, Mahony J, Chen Z, 
Reantragoon R, Meehan B, Cao H, et al. T-cell activation by transitory neo-antigens 
derived from distinct microbial pathways. Nature. 2014;509(7500). 
30. Awad W, Ler GJM, Xu W, Keller AN, Mak JYW, Lim XY, Liu L, Eckle SBG, Le 
Nours J, McCluskey J, et al. The molecular basis underpinning the potency and 
specificity of MAIT cell antigens. Nature Immunology. 2020;21(4):400-11. 
 
 51 
31. Keller AN, Eckle SBG, Xu W, Liu L, Hughes VA, Mak JYW, Meehan BS, 
Pediongco T, Birkinshaw RW, Chen Z, et al. Drugs and drug-like molecules can 
modulate the function of mucosal-associated invariant T cells. Nature Immunology. 
2017;18(4):402-11. 
32. Salio M, Awad W, Veerapen N, Gonzalez-Lopez C, Kulicke C, Waithe D, Martens 
AWJ, Lewinsohn DM, Hobrath JV, Cox LR, et al. Ligand-dependent downregulation 
of MR1 cell surface expression. Proceedings of the National Academy of Sciences. 
2020;117(19):10465-75. 
33. Hashimoto K, Hirai M, and Kurosawa Y. A gene outside the human MHC related to 
classical HLA class I genes. Science. 1995;269(5224):693-5. 
34. Boudinot P, Mondot S, Jouneau L, Teyton L, Lefranc M-P, and Lantz O. Restricting 
nonclassical MHC genes coevolve with TRAV genes used by innate-like T cells in 
mammals. Proceedings of the National Academy of Sciences. 2016;113(21). 
35. Huang S, Gilfillan S, Kim S, Thompson B, Wang X, Sant AJ, Fremont DH, Lantz O, 
and Hansen TH. MR1 uses an endocytic pathway to activate mucosal-associated 
invariant T cells. The Journal of Experimental Medicine. 2008;205(5):1201-11. 
36. Tsukamoto K, Deakin JE, Graves JA, and Hashimoto K. Exceptionally high 
conservation of the MHC class I-related gene, MR1, among mammals. 
Immunogenetics. 2013;65(2):115-24. 
37. Leeansyah E, Hey YY, Sia WR, Ng JHJ, Gulam MY, Boulouis C, Zhu F, Ahn M, 
Mak JYW, Fairlie DP, et al. MR1-Restricted T Cells with MAIT-like Characteristics 
Are Functionally Conserved in the Pteropid Bat Pteropus alecto. iScience. 
2020;23(12):101876. 
38. McWilliam HEG, Eckle SBG, Theodossis A, Liu L, Chen Z, Wubben JM, Fairlie DP, 
Strugnell RA, Mintern JD, McCluskey J, et al. The intracellular pathway for the 
presentation of vitamin B–related antigens by the antigen-presenting molecule MR1. 
Nature Immunology. 2016;17(5):531-7. 
39. McWilliam HEG, Mak JYW, Awad W, Zorkau M, Cruz-Gomez S, Lim HJ, Yan Y, 
Wormald S, Dagley LF, Eckle SBG, et al. Endoplasmic reticulum chaperones 
stabilize ligand-receptive MR1 molecules for efficient presentation of metabolite 
antigens. Proceedings of the National Academy of Sciences. 2020;117(40):24974-85. 
40. Harriff MJ, Karamooz E, Burr A, Grant WF, Canfield ET, Sorensen ML, Moita LF, 
and Lewinsohn DM. Endosomal MR1 Trafficking Plays a Key Role in Presentation 
of Mycobacterium tuberculosis Ligands to MAIT Cells. PLOS Pathogens. 
2016;12(3). 
41. Karamooz E, Harriff MJ, Narayanan GA, Worley A, and Lewinsohn DM. MR1 
recycling and blockade of endosomal trafficking reveal distinguishable antigen 
presentation pathways between Mycobacterium tuberculosis infection and 
exogenously delivered antigens. Scientific Reports. 2019;9(1). 
42. McWilliam H, and Villadangos JA. How MR1 Presents a Pathogen Metabolic 
Signature to Mucosal-Associated Invariant T (MAIT) Cells. Trends in Immunology. 
2017;38(9):679-89. 
43. Huber ME, Kurapova R, Heisler CM, Karamooz E, Tafesse FG, and Harriff MJ. 




44. McWilliam HEG, and Salio M. Understanding and modulating the MR1 metabolite 
antigen presentation pathway. Molecular Immunology. 2021;129(121-6. 
45. Pincikova T, Paquin-Proulx D, Moll M, Flodström-Tullberg M, Hjelte L, and 
Sandberg JK. Severely Impaired Control of Bacterial Infections in a Patient With 
Cystic Fibrosis Defective in Mucosal-Associated Invariant T Cells. Chest. 
2018;153(5):e93-e6. 
46. Howson LJ, Awad W, von Borstel A, Lim HJ, McWilliam HEG, Sandoval-Romero 
ML, Majumdar S, Hamzeh AR, Andrews TD, McDermott DH, et al. Absence of 
mucosal-associated invariant T cells in a person with a homozygous point mutation in 
MR1. Science immunology. 2020;5(49). 
47. Dusseaux M, Martin E, Serriari N, Péguillet I, Premel V, Louis D, Milder M, Le 
Bourhis L, Soudais C, Treiner E, et al. Human MAIT cells are xenobiotic-resistant, 
tissue-targeted, CD161<sup>hi</sup> IL-17–secreting T cells. Blood. 
2011;117(4):1250-9. 
48. Meermeier EW, Laugel BF, Sewell AK, Corbett AJ, Rossjohn J, McCluskey J, 
Harriff MJ, Franks T, Gold MC, and Lewinsohn DM. Human TRAV1-2-negative 
MR1-restricted T cells detect S. pyogenes and alternatives to MAIT riboflavin-based 
antigens. Nature Communications. 2016;7(12506. 
49. Reantragoon R, Corbett AJ, Sakala IG, Gherardin NA, Furness JB, Chen Z, Eckle 
SBG, Uldrich AP, Birkinshaw RW, Patel O, et al. Antigen-loaded MR1 tetramers 
define T cell receptor heterogeneity in mucosal-associated invariant T cells. The 
Journal of Experimental Medicine. 2013;210(11):2305-20. 
50. Amini A, Pang D, Hackstein CP, and Klenerman P. MAIT Cells in Barrier Tissues: 
Lessons from Immediate Neighbors. Front Immunol. 2020;11(584521. 
51. Sobkowiak MJ, Davanian H, Heymann R, Gibbs A, Emgård J, Dias J, Aleman S, 
Krüger-Weiner C, Moll M, Tjernlund A, et al. Tissue-resident MAIT cell populations 
in human oral mucosa exhibit an activated profile and produce IL-17. European 
Journal of Immunology. 2018;49(1):133-43. 
52. D’Souza C, Pediongco T, Wang H, Scheerlinck J-PY, Kostenko L, Esterbauer R, 
Stent AW, Eckle SBG, Meehan BS, Strugnell RA, et al. Mucosal-Associated 
Invariant T Cells Augment Immunopathology and Gastritis in ChronicHelicobacter 
pyloriInfection. The Journal of Immunology. 2018. 
53. Schmaler M, Colone A, Spagnuolo J, Zimmermann M, Lepore M, Kalinichenko A, 
Bhatia S, Cottier F, Rutishauser T, Pavelka N, et al. Modulation of bacterial 
metabolism by the microenvironment controls MAIT cell stimulation. Mucosal 
Immunology. 2018;11(4):1060-70. 
54. Jo J, Tan AT, Ussher JE, Sandalova E, Tang X-Z, Tan-Garcia A, To N, Hong M, 
Chia A, Gill US, et al. Toll-Like Receptor 8 Agonist and Bacteria Trigger Potent 
Activation of Innate Immune Cells in Human Liver. PLOS Pathogens. 
2014;10(6):e1004210. 
55. Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J, Winata E, 
Swarbrick GM, Chua WJ, Yu YY, et al. Human mucosal associated invariant T cells 
detect bacterially infected cells. PLoS Biol. 2010;8(6):e1000407. 
56. Teunissen MBM, Yeremenko NG, Baeten DLP, Chielie S, Spuls PI, de Rie MA, 
Lantz O, and Res PCM. The IL-17A-Producing CD8 + T-Cell Population in Psoriatic 
 
 53 
Lesional Skin Comprises Mucosa-Associated Invariant T Cells and Conventional T 
Cells. Journal of Investigative Dermatology. 2014;134(12):2898-907. 
57. Gibbs A, Leeansyah E, Introini A, Paquin-Proulx D, Hasselrot K, Andersson E, 
Broliden K, Sandberg JK, and Tjernlund A. MAIT cells reside in the female genital 
mucosa and are biased towards IL-17 and IL-22 production in response to bacterial 
stimulation. Mucosal Immunol. 2017;10(1):35-45. 
58. Sallusto F, Lenig D, Förster R, Lipp M, and Lanzavecchia A. Two subsets of memory 
T lymphocytes with distinct homing potentials and effector functions. Nature. 
1999;401(6754):708-12. 
59. Voillet V, Buggert M, Slichter CK, Berkson JD, Mair F, Addison MM, Dori Y, 
Nadolski G, Itkin MG, Gottardo R, et al. Human MAIT cells exit peripheral tissues 
and recirculate via lymph in steady state conditions. JCI Insight. 2018;3(7). 
60. Lee CH, Zhang HH, Singh SP, Koo L, Kabat J, Tsang H, Singh TP, and Farber JM. 
C/EBPδ drives interactions between human MAIT cells and endothelial cells that are 
important for extravasation. eLife. 2018;7( 
61. Kurioka A, Jahun AS, Hannaway RF, Walker LJ, Fergusson JR, Sverremark-Ekström 
E, Corbett AJ, Ussher JE, Willberg CB, and Klenerman P. Shared and Distinct 
Phenotypes and Functions of Human CD161++ Vα7.2+ T Cell Subsets. Frontiers in 
Immunology. 2017;8(1031. 
62. Jensen O, Trivedi S, Meier JD, Fairfax K, Scott Hale J, and Leung DT. A novel 
subset of follicular helper-like MAIT cells has capacity for B cell help and antibody 
production in the mucosa. bioRxiv. 2020:2020.10.05.326488. 
63. Legoux F, Bellet D, Daviaud C, El Morr Y, Darbois A, Niort K, Procopio E, Salou 
M, Gilet J, Ryffel B, et al. Microbial metabolites control the thymic development of 
mucosal-associated invariant T cells. Science. 2019;366(6464):494-9. 
64. Salou M, Legoux F, Gilet J, Darbois A, du Halgouet A, Alonso R, Richer W, Goubet 
AG, Daviaud C, Menger L, et al. A common transcriptomic program acquired in the 
thymus defines tissue residency of MAIT and NKT subsets. J Exp Med. 
2019;216(1):133-51. 
65. Lamichhane R, Galvin H, Hannaway RF, la Harpe SM, Munro F, Tyndall JDA, 
Vernall AJ, McCall JL, Husain M, and Ussher JE. Type I interferons are important 
co-stimulatory signals during T cell receptor mediated human MAIT cell activation. 
European Journal of Immunology. 2019;50(2):178-91. 
66. Provine NM, and Klenerman P. MAIT Cells in Health and Disease. Annu Rev 
Immunol. 2020;38(203-28. 
67. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F, Affaticati P, 
Gilfillan S, and Lantz O. Selection of evolutionarily conserved mucosal-associated 
invariant T cells by MR1. Nature. 2003;422(6928):164-9. 
68. Martin E, Treiner E, Duban L, Guerri L, Laude H, Toly C, Premel V, Devys A, 
Moura IC, Tilloy F, et al. Stepwise development of MAIT cells in mouse and human. 
PLoS Biol. 2009;7(3):e54. 
69. Koay H-F, Gherardin NA, Enders A, Loh L, Mackay LK, Almeida CF, Russ BE, 
Nold-Petry CA, Nold MF, Bedoui S, et al. A three-stage intrathymic development 
 
54 
pathway for the mucosal-associated invariant T cell lineage. Nature Immunology. 
2016;17(11):1300-11. 
70. Youssef G, Tourret M, Salou M, Ghazarian L, Houdouin V, Mondot S, Mburu Y, 
Lambert M, Azarnoush S, Diana J-S, et al. Ontogeny of human mucosal-associated 
invariant T cells and related T cell subsets. Journal of Experimental Medicine. 
2018;215(2). 
71. Constantinides MG, Link VM, Tamoutounour S, Wong AC, Perez-Chaparro PJ, Han 
SJ, Chen YE, Li K, Farhat S, Weckel A, et al. MAIT cells are imprinted by the 
microbiota in early life and promote tissue repair. Science. 2019;366(6464). 
72. Pellicci DG, Koay H-F, and Berzins SP. Thymic development of unconventional T 
cells: how NKT cells, MAIT cells and γδ T cells emerge. Nature Reviews 
Immunology. 2020;20(12):756-70. 
73. Legoux F, Salou M, and Lantz O. MAIT Cell Development and Functions: the 
Microbial Connection. Immunity. 2020;53(4):710-23. 
74. Yang R, Mele F, Worley L, Langlais D, Rosain J, Benhsaien I, Elarabi H, Croft CA, 
Doisne J-M, Zhang P, et al. Human T-bet Governs Innate and Innate-like Adaptive 
IFN-γ Immunity against Mycobacteria. Cell. 2020;183(7):1826-47.e31. 
75. Koay H-F, Gherardin NA, Xu C, Seneviratna R, Zhao Z, Chen Z, Fairlie DP, 
McCluskey J, Pellicci DG, Uldrich AP, et al. Diverse MR1-restricted T cells in mice 
and humans. Nature Communications. 2019;10(1). 
76. Leeansyah E, Loh L, Nixon DF, and Sandberg JK. Acquisition of innate-like 
microbial reactivity in mucosal tissues during human fetal MAIT-cell development. 
Nat Commun. 2014;5(3143. 
77. Loh L, Gherardin NA, Sant S, Grzelak L, Crawford JC, Bird NL, Koay H-F, van de 
Sandt CE, Moreira ML, Lappas M, et al. Human Mucosal-Associated Invariant T 
Cells in Older Individuals Display Expanded TCRαβ Clonotypes with Potent 
Antimicrobial Responses. The Journal of Immunology. 2020;204(5):1119-33. 
78. Tang X-Z, Jo J, Tan AT, Sandalova E, Chia A, Tan KC, Lee KH, Gehring AJ, De 
Libero G, and Bertoletti A. IL-7 Licenses Activation of Human Liver Intrasinusoidal 
Mucosal-Associated Invariant T Cells. The Journal of Immunology. 
2013;190(7):3142-52. 
79. Barata JT, Durum SK, and Seddon B. Flip the coin: IL-7 and IL-7R in health and 
disease. Nature Immunology. 2019;20(12):1584-93. 
80. Sortino O, Dias J, Anderson M, Laidlaw E, Leeansyah E, Lisco A, Sheikh V, 
Sandberg JK, and Sereti I. Preserved MAIT cell numbers and function in idiopathic 
CD4 lymphocytopenia. J Infect Dis. 2020. 
81. Sortino O, Richards E, Dias J, Leeansyah E, Sandberg JK, and Sereti I. IL-7 treatment 
supports CD8+ mucosa-associated invariant T-cell restoration in HIV-1-infected 
patients on antiretroviral therapy. Aids. 2018;32(6):825-8. 
82. Leeansyah E, Svard J, Dias J, Buggert M, Nystrom J, Quigley MF, Moll M, 
Sonnerborg A, Nowak P, and Sandberg JK. Arming of MAIT Cell Cytolytic 




83. Kurioka A, Ussher JE, Cosgrove C, Clough C, Fergusson JR, Smith K, Kang YH, 
Walker LJ, Hansen TH, Willberg CB, et al. MAIT cells are licensed through 
granzyme exchange to kill bacterially sensitized targets. Mucosal Immunol. 
2015;8(2):429-40. 
84. Wilson RP, Ives ML, Rao G, Lau A, Payne K, Kobayashi M, Arkwright PD, Peake J, 
Wong M, Adelstein S, et al. STAT3 is a critical cell-intrinsic regulator of human 
unconventional T cell numbers and function. Journal of Experimental Medicine. 
2015;212(6):855-64. 
85. Dias J, Leeansyah E, and Sandberg JK. Multiple layers of heterogeneity and subset 
diversity in human MAIT cell responses to distinct microorganisms and to innate 
cytokines. Proc Natl Acad Sci U S A. 2017;114(27):E5434-E43. 
86. Lamichhane R, Schneider M, de la Harpe SM, Harrop TWR, Hannaway RF, Dearden 
PK, Kirman JR, Tyndall JDA, Vernall AJ, and Ussher JE. TCR- or Cytokine-
Activated CD8+ Mucosal-Associated Invariant T Cells Are Rapid Polyfunctional 
Effectors That Can Coordinate Immune Responses. Cell Reports. 2019;28(12):3061-
76.e5. 
87. Leng T, Akther HD, Hackstein C-P, Powell K, King T, Friedrich M, Christoforidou 
Z, McCuaig S, Neyazi M, Arancibia-Cárcamo CV, et al. TCR and Inflammatory 
Signals Tune Human MAIT Cells to Exert Specific Tissue Repair and Effector 
Functions. Cell Reports. 2019;28(12):3077-91.e5. 
88. Turtle CJ, Delrow J, Joslyn RC, Swanson HM, Basom R, Tabellini L, Delaney C, 
Heimfeld S, Hansen JA, and Riddell SR. Innate signals overcome acquired TCR 
signaling pathway regulation and govern the fate of human CD161hi CD8α+ semi-
invariant T cells. Blood. 2011;118(10):2752-62. 
89. Slichter CK, McDavid A, Miller HW, Finak G, Seymour BJ, McNevin JP, Diaz G, 
Czartoski JL, McElrath MJ, Gottardo R, et al. Distinct activation thresholds of human 
conventional and innate-like memory T cells. JCI Insight. 2016;1(8). 
90. Hinks TSC, Marchi E, Jabeen M, Olshansky M, Kurioka A, Pediongco TJ, Meehan 
BS, Kostenko L, Turner SJ, Corbett AJ, et al. Activation and In Vivo Evolution of the 
MAIT Cell Transcriptome in Mice and Humans Reveals Tissue Repair Functionality. 
Cell Reports. 2019;28(12):3249-62.e5. 
91. Chen Z, Wang H, D'Souza C, Sun S, Kostenko L, Eckle SB, Meehan BS, Jackson 
DC, Strugnell RA, Cao H, et al. Mucosal-associated invariant T-cell activation and 
accumulation after in vivo infection depends on microbial riboflavin synthesis and co-
stimulatory signals. Mucosal Immunol. 2017;10(1):58-68. 
92. Sattler A, Thiel LG, Ruhm AH, Souidi N, Seifert M, Herberth G, and Kotsch K. The 
TL1A-DR3 Axis Selectively Drives Effector Functions in Human MAIT Cells. The 
Journal of Immunology. 2019;203(11):2970-8. 
93. Ussher JE, Bilton M, Attwod E, Shadwell J, Richardson R, Lara C, Mettke E, 
Kurioka A, Hansen TH, Klenerman P, et al. CD161++CD8+ T cells, including the 
MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent 
manner. European Journal of Immunology. 2014;44(1):195-203. 
94. Sattler A, Dang-Heine C, Reinke P, and Babel N. IL-15 dependent induction of IL-18 
secretion as a feedback mechanism controlling human MAIT-cell effector functions. 
European Journal of Immunology. 2015;45(8):2286-98. 
 
56 
95. van Wilgenburg B, Loh L, Chen Z, Pediongco TJ, Wang H, Shi M, Zhao Z, 
Koutsakos M, Nüssing S, Sant S, et al. MAIT cells contribute to protection against 
lethal influenza infection in vivo. Nat Commun. 2018;9(1):4706. 
96. van Wilgenburg B, Scherwitzl I, Hutchinson EC, Leng T, Kurioka A, Kulicke C, de 
Lara C, Cole S, Vasanawathana S, Limpitikul W, et al. MAIT cells are activated 
during human viral infections. Nature Communications. 2016;7(11653. 
97. Slichter CK, McDavid A, Miller HW, Finak G, Seymour BJ, McNevin JP, Diaz G, 
Czartoski JL, McElrath JM, Gottardo R, et al. Distinct activation thresholds of human 
conventional and innate-like memory T cells. JCI Insight. 2016;1(8). 
98. Dias J, Sobkowiak MJ, Sandberg JK, and Leeansyah E. Human MAIT-cell responses 
to Escherichia coli: activation, cytokine production, proliferation, and cytotoxicity. J 
Leukoc Biol. 2016;100(1):233-40. 
99. Böttcher S, Hartung S, Meyer F, Rummler S, Voigt K, Walther G, Hochhaus A, von 
Lilienfeld-Toal M, and Jahreis S. Human mucosal-associated invariant T cells 
respond to Mucorales species in a MR1-dependent manner. Medical Mycology. 2020. 
100. Jahreis S, Böttcher S, Hartung S, Rachow T, Rummler S, Dietl A-M, Haas H, Walther 
G, Hochhaus A, and von Lilienfeld-Toal M. Human MAIT cells are rapidly activated 
by Aspergillus spp. in an APC-dependent manner. European Journal of Immunology. 
2018;48(10):1698-706. 
101. Howson LJ, Napolitani G, Shepherd D, Ghadbane H, Kurupati P, Preciado-Llanes L, 
Rei M, Dobinson HC, Gibani MM, Teng KWW, et al. MAIT cell clonal expansion 
and TCR repertoire shaping in human volunteers challenged with Salmonella 
Paratyphi A. Nat Commun. 2018;9(1):253. 
102. Salerno-Goncalves R, Luo D, Fresnay S, Magder L, Darton TC, Jones C, Waddington 
CS, Blohmke CJ, Angus B, Levine MM, et al. Challenge of Humans with Wild-type 
Salmonella enterica Serovar Typhi Elicits Changes in the Activation and Homing 
Characteristics of Mucosal-Associated Invariant T Cells. Frontiers in Immunology. 
2017;8(398. 
103. Le Bourhis L, Dusseaux M, Bohineust A, Bessoles S, Martin E, Premel V, Core M, 
Sleurs D, Serriari NE, Treiner E, et al. MAIT cells detect and efficiently lyse 
bacterially-infected epithelial cells. PLoS Pathog. 2013;9(10):e1003681. 
104. Huang H, Sikora MJ, Islam S, Chowdhury RR, Chien Y-h, Scriba TJ, Davis MM, and 
Steinmetz LM. Select sequencing of clonally expanded CD8+ T cells reveals limits to 
clonal expansion. Proceedings of the National Academy of Sciences. 
2019;116(18):8995-9001. 
105. Kurioka A, van Wilgenburg B, Javan RR, Hoyle R, van Tonder AJ, Harrold CL, Leng 
T, Howson LJ, Shepherd D, Cerundolo V, et al. Diverse Streptococcus pneumoniae 
Strains Drive a Mucosal-Associated Invariant T-Cell Response Through Major 
Histocompatibility Complex class I–Related Molecule–Dependent and Cytokine-
Driven Pathways. The Journal of Infectious Diseases. 2018;217(6):988-99. 
106. Salio M, Gasser O, Gonzalez-Lopez C, Martens A, Veerapen N, Gileadi U, Verter 
JG, Napolitani G, Anderson R, Painter G, et al. Activation of Human Mucosal-
Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-
Derived and Primary Dendritic Cells. J Immunol. 2017;199(8):2631-8. 
 
 57 
107. Ussher JE, van Wilgenburg B, Hannaway RF, Ruustal K, Phalora P, Kurioka A, 
Hansen TH, Willberg CB, Phillips RE, and Klenerman P. TLR signaling in human 
antigen-presenting cells regulates MR1-dependent activation of MAIT cells. 
European Journal of Immunology. 2016;46(7):1600-14. 
108. Jeffery HC, van Wilgenburg B, Kurioka A, Parekh K, Stirling K, Roberts S, Dutton 
EE, Hunter S, Geh D, Braitch MK, et al. Biliary epithelium and liver B cells exposed 
to bacteria activate intrahepatic MAIT cells through MR1. Journal of Hepatology. 
2016;64(5):1118-27. 
109. Carolan E, Tobin LM, Mangan BA, Corrigan M, Gaoatswe G, Byrne G, Geoghegan 
J, Cody D, O’Connell J, Winter DC, et al. Altered Distribution and Increased IL-17 
Production by Mucosal-Associated Invariant T Cells in Adult and Childhood Obesity. 
The Journal of Immunology. 2015;194(12):5775-80. 
110. Lu B, Liu M, Wang J, Fan H, Yang D, Zhang L, Gu X, Nie J, Chen Z, Corbett AJ, et 
al. IL-17 production by tissue-resident MAIT cells is locally induced in children with 
pneumonia. Mucosal Immunology. 2020;13(5):824-35. 
111. Voskoboinik I, Whisstock JC, and Trapani JA. Perforin and granzymes: function, 
dysfunction and human pathology. Nature Reviews Immunology. 2015;15(6):388-400. 
112. Wensink AC, Hack CE, and Bovenschen N. Granzymes Regulate Proinflammatory 
Cytokine Responses. The Journal of Immunology. 2015;194(2):491-7. 
113. Dotiwala F, Sen Santara S, Binker-Cosen AA, Li B, Chandrasekaran S, and 
Lieberman J. Granzyme B Disrupts Central Metabolism and Protein Synthesis in 
Bacteria to Promote an Immune Cell Death Program. Cell. 2017;171(5):1125-37.e11. 
114. Walch M, Dotiwala F, Mulik S, Thiery J, Kirchhausen T, Clayberger C, Krensky 
Alan M, Martinvalet D, and Lieberman J. Cytotoxic Cells Kill Intracellular Bacteria 
through Granulysin-Mediated Delivery of Granzymes. Cell. 2014;157(6):1309-23. 
115. Huang LP, Lyu S-C, Clayberger C, and Krensky AM. Granulysin-Mediated Tumor 
Rejection in Transgenic Mice. The Journal of Immunology. 2007;178(1):77-84. 
116. Leeansyah E, Boulouis C, Kwa ALH, and Sandberg JK. Emerging Role for MAIT 
Cells in Control of Antimicrobial Resistance. Trends in Microbiology. 2020. 
117. Wan Rong Sia CB, Muhammad Yaaseen Gulam, Andrea Lay Hoon Kwa, Johan K. 
Sandberg, and Edwin Leeansyah. In: Helen Kaiper IM ed. MAIT cells Methods and 
Protocols. Springer Protocols; 2020. 
118. Leng T, Akther HD, Hackstein CP, Powell K, King T, Friedrich M, Christoforidou Z, 
McCuaig S, Neyazi M, Arancibia-Cárcamo CV, et al. TCR and Inflammatory Signals 
Tune Human MAIT Cells to Exert Specific Tissue Repair and Effector Functions. 
Cell Rep. 2019;28(12):3077-91.e5. 
119. Meller S, Di Domizio J, Voo KS, Friedrich HC, Chamilos G, Ganguly D, Conrad C, 
Gregorio J, Le Roy D, Roger T, et al. TH17 cells promote microbial killing and innate 
immune sensing of DNA via interleukin 26. Nature Immunology. 2015;16(9):970-9. 
120. Guesdon W, Auray G, Pezier T, Bussière FI, Drouet F, Le Vern Y, Marquis M, 
Potiron L, Rabot S, Bruneau A, et al. CCL20 Displays Antimicrobial Activity 
AgainstCryptosporidium parvum, but Its Expression Is Reduced During Infection in 
the Intestine of Neonatal Mice. Journal of Infectious Diseases. 2015;212(8):1332-40. 
 
58 
121. Margulieux KR, Fox JW, Nakamoto RK, and Hughes MA. CXCL10 Acts as a 
Bifunctional Antimicrobial Molecule against Bacillus anthracis. mBio. 2016;7(3). 
122. Reid-Yu SA, Tuinema BR, Small CN, Xing L, and Coombes BK. CXCL9 contributes 
to antimicrobial protection of the gut during citrobacter rodentium infection 
independent of chemokine-receptor signaling. PLoS Pathog. 2015;11(2):e1004648. 
123. Wang H, D’Souza C, Lim XY, Kostenko L, Pediongco TJ, Eckle SBG, Meehan BS, 
Shi M, Wang N, Li S, et al. MAIT cells protect against pulmonary Legionella 
longbeachae infection. Nature Communications. 2018;9(1). 
124. Meierovics A, Yankelevich WJ, and Cowley SC. MAIT cells are critical for optimal 
mucosal immune responses during in vivo pulmonary bacterial infection. Proc Natl 
Acad Sci U S A. 2013;110(33):E3119-28. 
125. Chua WJ, Truscott SM, Eickhoff CS, Blazevic A, Hoft DF, and Hansen TH. 
Polyclonal mucosa-associated invariant T cells have unique innate functions in 
bacterial infection. Infect Immun. 2012;80(9):3256-67. 
126. Sakai S, Kauffman KD, Oh S, Nelson CE, Barry CE, and Barber DL. MAIT cell-
directed therapy of Mycobacterium tuberculosis infection. Mucosal Immunology. 
2020;14(1):199-208. 
127. Georgel P, Radosavljevic M, Macquin C, and Bahram S. The non-conventional MHC 
class I MR1 molecule controls infection by Klebsiella pneumoniae in mice. 
Molecular Immunology. 2011;48(5):769-75. 
128. Wang H, Kjer-Nielsen L, Shi M, D'Souza C, Pediongco TJ, Cao H, Kostenko L, Lim 
XY, Eckle SBG, Meehan BS, et al. IL-23 costimulates antigen-specific MAIT cell 
activation and enables vaccination against bacterial infection. Science immunology. 
2019;4(41). 
129. Meierovics AI, and Cowley SC. MAIT cells promote inflammatory monocyte 
differentiation into dendritic cells during pulmonary intracellular infection. Journal of 
Experimental Medicine. 2016;213(12). 
130. Sakala IG, Kjer-Nielsen L, Eickhoff CS, Wang X, Blazevic A, Liu L, Fairlie DP, 
Rossjohn J, McCluskey J, Fremont DH, et al. Functional Heterogeneity and 
Antimycobacterial Effects of Mouse Mucosal-Associated Invariant T Cells Specific 
for Riboflavin Metabolites. The Journal of Immunology. 2015;195(2):587-601. 
131. Hartmann N, McMurtrey C, Sorensen ML, Huber ME, Kurapova R, Coleman FT, 
Mizgerd JP, Hildebrand W, Kronenberg M, Lewinsohn DM, et al. Riboflavin 
Metabolism Variation Among Clinical Isolates of Streptococcus pneumoniae Results 
in Differential Activation of MAIT Cells. American Journal of Respiratory Cell and 
Molecular Biology. 2018. 
132. Preciado-Llanes L, Aulicino A, Canals R, Moynihan PJ, Zhu X, Jambo N, Nyirenda 
TS, Kadwala I, Sousa Gerós A, Owen SV, et al. Evasion of MAIT cell recognition by 
the AfricanSalmonellaTyphimurium ST313 pathovar that causes invasive disease. 
Proceedings of the National Academy of Sciences. 2020;117(34):20717-28. 
133. Bister J, Crona Guterstam Y, Strunz B, Dumitrescu B, Haij Bhattarai K, Özenci V, 
Brännström M, Ivarsson MA, Gidlöf S, and Björkström NK. Human endometrial 
MAIT cells are transiently tissue resident and respond to Neisseria gonorrhoeae. 
Mucosal Immunology. 2020. 
 
 59 
134. Jiang J, Chen X, An H, Yang B, Zhang F, and Cheng X. Enhanced immune response 
of MAIT cells in tuberculous pleural effusions depends on cytokine signaling. 
Scientific Reports. 2016;6(1):32320. 
135. Coakley JD, Breen EP, Moreno-Olivera A, Al-Harbi AI, Melo AM, O’Connell B, 
McManus R, Doherty DG, and Ryan T. Innate Lymphocyte Th1 and Th17 Responses 
in Elderly Hospitalised Patients with Infection and Sepsis. Vaccines. 2020;8(2):311. 
136. Pomaznoy M, Kuan R, Lindvall M, Burel JG, Seumois G, Vijayanand P, Taplitz R, 
Gilman RH, Saito M, Lewinsohn DM, et al. Quantitative and Qualitative 
Perturbations of CD8(+) MAITs in Healthy Mycobacterium tuberculosis-Infected 
Individuals. Immunohorizons. 2020;4(6):292-307. 
137. Terpstra ML, Remmerswaal EBM, Aalderen MC, Wever JJ, Sinnige MJ, Bom-
Baylon ND, Bemelman FJ, and Geerlings SE. Circulating mucosal-associated 
invariant T cells in subjects with recurrent urinary tract infections are functionally 
impaired. Immunity, Inflammation and Disease. 2020;8(1):80-92. 
138. Suliman S, Gela A, Mendelsohn SC, Iwany SK, Tamara KL, Mabwe S, Bilek N, 
Darboe F, Fisher M, Corbett AJ, et al. Peripheral Blood Mucosal-Associated Invariant 
T Cells in Tuberculosis Patients and Healthy Mycobacterium tuberculosis-Exposed 
Controls. J Infect Dis. 2020;222(6):995-1007. 
139. Jochems SP, de Ruiter K, Solórzano C, Voskamp A, Mitsi E, Nikolaou E, Carniel BF, 
Pojar S, German EL, Reiné J, et al. Innate and adaptive nasal mucosal immune 
responses following experimental human pneumococcal colonization. Journal of 
Clinical Investigation. 2019;129(10):4523-38. 
140. Bennett MS, Trivedi S, Iyer AS, Hale SJ, and Leung DT. Human mucosal-associated 
invariant T (MAIT) cells possess capacity for B cell help. Journal of Leukocyte 
Biology. 2017;102(5):1261-9. 
141. Rahman MA, Ko E-J, Bhuyan F, Enyindah-Asonye G, Hunegnaw R, Helmold Hait S, 
Hogge CJ, Venzon DJ, Hoang T, and Robert-Guroff M. Mucosal-associated invariant 
T (MAIT) cells provide B-cell help in vaccinated and subsequently SIV-infected 
Rhesus Macaques. Scientific Reports. 2020;10(1). 
142. Murayama G, Chiba A, Suzuki H, Nomura A, Mizuno T, Kuga T, Nakamura S, 
Amano H, Hirose S, Yamaji K, et al. A Critical Role for Mucosal-Associated 
Invariant T Cells as Regulators and Therapeutic Targets in Systemic Lupus 
Erythematosus. Frontiers in Immunology. 2019;10( 
143. Davey MS, Morgan MP, Liuzzi AR, Tyler CJ, Khan MWA, Szakmany T, Hall JE, 
Moser B, and Eberl M. Microbe-Specific Unconventional T Cells Induce Human 
Neutrophil Differentiation into Antigen Cross-Presenting Cells. The Journal of 
Immunology. 2014;193(7):3704-16. 
144. Schneider M, Hannaway RF, Lamichhane R, Harpe SM, Tyndall JDA, Vernall AJ, 
Kettle AJ, and Ussher JE. Neutrophils suppress mucosal-associated invariant T cells 
in humans. European Journal of Immunology. 2020;50(5):643-55. 
145. Loh L, Wang Z, Sant S, Koutsakos M, Jegaskanda S, Corbett AJ, Liu L, Fairlie DP, 
Crowe J, Rossjohn J, et al. Human mucosal-associated invariant T cells contribute to 
antiviral influenza immunity via IL-18–dependent activation. Proceedings of the 
National Academy of Sciences. 2016;113(36):10133-8. 
 
60 
146. Dias J, Hengst J, Parrot T, Leeansyah E, Lunemann S, Malone DFG, Hardtke S, 
Strauss O, Zimmer CL, Berglin L, et al. Chronic hepatitis delta virus infection leads 
to functional impairment and severe loss of MAIT cells. Journal of Hepatology. 
2019;71(2):301-12. 
147. Lal K, Phuang-Ngern Y, Suhkumvittaya S, Leeansyah E, Alrubayyi A, Dias J, 
Waickman A, Kim D, Kroon E, Pinyakorn S, et al. Longitudinal Analysis of 
Peripheral and Colonic CD161+ CD4+ T Cell Dysfunction in Acute HIV-1 Infection 
and Effects of Early Treatment Initiation. Viruses. 2020;12(12):1426. 
148. Paquin-Proulx D, Avelino-Silva V, Santos BAN, Barsotti N, Siroma F, Ramos J, 
Tonacio A, Song A, Maestri A, Cerqueira N, et al. MAIT cells are activated in acute 
Dengue virus infection and after in vitro Zika virus infection. PLOS Neglected 
Tropical Diseases. 2018;12(1). 
149. Parrot T, Gorin JB, Ponzetta A, Maleki KT, Kammann T, Emgård J, Perez-Potti A, 
Sekine T, Rivera-Ballesteros O, Gredmark-Russ S, et al. MAIT cell activation and 
dynamics associated with COVID-19 disease severity. Science immunology. 
2020;5(51). 
150. Flament H, Rouland M, Beaudoin L, Toubal A, Bertrand L, Lebourgeois S, Rousseau 
C, Soulard P, Gouda Z, Cagninacci L, et al. Outcome of SARS-CoV-2 infection is 
linked to MAIT cell activation and cytotoxicity. Nature Immunology. 2021. 
151. Leeansyah E, Ganesh A, Quigley MF, Sonnerborg A, Andersson J, Hunt PW, 
Somsouk M, Deeks SG, Martin JN, Moll M, et al. Activation, exhaustion, and 
persistent decline of the antimicrobial MR1-restricted MAIT-cell population in 
chronic HIV-1 infection. Blood. 2013;121(7):1124-35. 
152. Rudak PT, Choi J, and Haeryfar SMM. MAIT cell-mediated cytotoxicity: Roles in 
host defense and therapeutic potentials in infectious diseases and cancer. J Leukoc 
Biol. 2018;104(3):473-86. 
153. Hengst J, Strunz B, Deterding K, Ljunggren HG, Leeansyah E, Manns MP, Cornberg 
M, Sandberg JK, Wedemeyer H, and Björkström NK. Nonreversible MAIT cell-
dysfunction in chronic hepatitis C virus infection despite successful interferon-free 
therapy. European Journal of Immunology. 2016;46(9):2204-10. 
154. Corbett AJ, Awad W, Wang H, and Chen Z. Antigen Recognition by MR1-Reactive 
T Cells; MAIT Cells, Metabolites, and Remaining Mysteries. Frontiers in 
Immunology. 2020;11( 
155. Lal KG, Kim D, Costanzo MC, Creegan M, Leeansyah E, Dias J, Paquin-Proulx D, 
Eller LA, Schuetz A, Phuang-ngern Y, et al. Dynamic MAIT cell response with 
progressively enhanced innateness during acute HIV-1 infection. Nature 
Communications. 2020;11(1). 
156. Dias J, Boulouis C, Gorin J-B, van den Biggelaar RHGA, Lal KG, Gibbs A, Loh L, 
Gulam MY, Sia WR, Bari S, et al. The CD4−CD8− MAIT cell subpopulation is a 
functionally distinct subset developmentally related to the main CD8+ MAIT cell 
pool. Proceedings of the National Academy of Sciences. 2018;115(49):E11513-E22. 
157. Crowther MD, Dolton G, Legut M, Caillaud ME, Lloyd A, Attaf M, Galloway SAE, 
Rius C, Farrell CP, Szomolay B, et al. Genome-wide CRISPR-Cas9 screening reveals 
ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein 
MR1. Nat Immunol. 2020;21(2):178-85. 
 
 61 
158. O'Neill J. Review on Antimicrobial resistace. Antimicrobial resistance: tacklinga 
crisis for the health and wealth of Nations. 
159. Hiltunen T, Virta M, and Laine AL. Antibiotic resistance in the wild: an eco-
evolutionary perspective. Philosophical transactions of the Royal Society of London 
Series B, Biological sciences. 2017;372(1712). 
160. Potter RF, D’Souza AW, and Dantas G. The rapid spread of carbapenem-resistant 
Enterobacteriaceae. Drug Resistance Updates. 2016;29(30-46. 
161. Ambler RP. The structure of beta-lactamases. Philosophical transactions of the Royal 
Society of London Series B, Biological sciences. 1980;289(1036):321-31. 
162. Cuchural GJ, Jr., Malamy MH, and Tally FP. Beta-lactamase-mediated imipenem 
resistance in Bacteroides fragilis. Antimicrob Agents Chemother. 1986;30(5):645-8. 
163. Nordmann P, Dortet L, and Poirel L. Carbapenem resistance in Enterobacteriaceae: 
here is the storm! Trends in Molecular Medicine. 2012;18(5):263-72. 
164. Tooke CL, Hinchliffe P, Bragginton EC, Colenso CK, Hirvonen VHA, Takebayashi 
Y, and Spencer J. β-Lactamases and β-Lactamase Inhibitors in the 21st Century. 
Journal of Molecular Biology. 2019;431(18):3472-500. 
165. Nordmann P, and Poirel L. Epidemiology and Diagnostics of Carbapenem Resistance 
in Gram-negative Bacteria. Clinical Infectious Diseases. 
2019;69(Supplement_7):S521-S8. 
166. Emery CL, and Weymouth LA. Detection and clinical significance of extended-
spectrum beta-lactamases in a tertiary-care medical center. Journal of clinical 
microbiology. 1997;35(8):2061-7. 
167. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, 
Huang X, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-
1 in animals and human beings in China: a microbiological and molecular biological 
study. The Lancet Infectious diseases. 2016;16(2):161-8. 
168. E.  Tacconelli NM. Global priority list of antibiotic-resistant bacteria to guide 
research, discovery, and developement of new antibiotics. WHO. 2017. 
169. Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, and Piddock LJV. Molecular 
mechanisms of antibiotic resistance. Nature Reviews Microbiology. 2014;13(1):42-
51. 
170. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, 
Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al. Multidrug-resistant, 
extensively drug-resistant and pandrug-resistant bacteria: an international expert 
proposal for interim standard definitions for acquired resistance. Clinical 
Microbiology and Infection. 2012;18(3):268-81. 
171. Mairpady Shambat S, Haggar A, Vandenesch F, Lina G, van Wamel WJ, Arakere G, 
Svensson M, and Norrby-Teglund A. Levels of alpha-toxin correlate with distinct 
phenotypic response profiles of blood mononuclear cells and with agr background of 
community-associated Staphylococcus aureus isolates. PLoS One. 
2014;9(8):e106107. 
172. Mak JYW, Xu W, Reid RC, Corbett AJ, Meehan BS, Wang H, Chen Z, Rossjohn J, 
McCluskey J, Liu L, et al. Stabilizing short-lived Schiff base derivatives of 5-
 
62 
aminouracils that activate mucosal-associated invariant T cells. Nature 
Communications. 2017;8(14599. 
173. Cossarizza A, Chang HD, Radbruch A, Acs A, Adam D, Adam-Klages S, Agace 
WW, Aghaeepour N, Akdis M, Allez M, et al. Guidelines for the use of flow 
cytometry and cell sorting in immunological studies (second edition). Eur J Immunol. 
2019;49(10):1457-973. 
174. Shapiro HM. Practical flow cytometry. Wiley-Liss; 2003. 
175. Maecker HT, and Trotter J. Flow cytometry controls, instrument setup, and the 
determination of positivity. Cytometry Part A. 2006;69A(9):1037-42. 
176. Perfetto SP, Ambrozak D, Nguyen R, Chattopadhyay P, and Roederer M. Quality 
assurance for polychromatic flow cytometry. Nature Protocols. 2006;1(3):1522-30. 
177. Roederer M. Compensation. http://drmr.com/compensation/. 
178. Nguyen R, Perfetto S, Mahnke YD, Chattopadhyay P, and Roederer M. Quantifying 
spillover spreading for comparing instrument performance and aiding in multicolor 
panel design. Cytometry Part A. 2013;83A(3):306-15. 
179. Perfetto SP, Ambrozak D, Nguyen R, Chattopadhyay PK, and Roederer M. Quality 
assurance for polychromatic flow cytometry using a suite of calibration beads. Nature 
Protocols. 2012;7(12):2067-79. 
180. Wang L, and Hoffman RA. Standardization, Calibration, and Control in Flow 
Cytometry. Current protocols in cytometry. 2017;79(1.3.1-.3.27. 
181. Boulouis C. The CS&T Report: Its Troubles, and How to Fix Them. 
https://bitesizebio.com/46384/the-cst-report-its-troubles-and-how-to-fix-them/. 
182. Guilliams M, Bruhns P, Saeys Y, Hammad H, and Lambrecht BN. The function of 
Fcgamma receptors in dendritic cells and macrophages. Nat Rev Immunol. 
2014;14(2):94-108. 
183. Nimmerjahn F, and Ravetch JV. Fcgamma receptors as regulators of immune 
responses. Nat Rev Immunol. 2008;8(1):34-47. 
184. Boross P, van Montfoort N, Stapels DA, van der Poel CE, Bertens C, Meeldijk J, 
Jansen JH, Verbeek JS, Ossendorp F, Wubbolts R, et al. FcRgamma-chain ITAM 
signaling is critically required for cross-presentation of soluble antibody-antigen 
complexes by dendritic cells. J Immunol. 2014;193(11):5506-14. 
185. Herrada AA, Contreras FJ, Tobar JA, Pacheco R, and Kalergis AM. Immune 
complex-induced enhancement of bacterial antigen presentation requires Fcgamma 
receptor III expression on dendritic cells. Proc Natl Acad Sci U S A. 
2007;104(33):13402-7. 
186. Trivedi V, Zhang SC, Castoreno AB, Stockinger W, Shieh EC, Vyas JM, Frickel E-
M, and Nohturfft A. Immunoglobulin G signaling activates lysosome/phagosome 
docking. Proceedings of the National Academy of Sciences. 2006;103(48):18226-31. 
187. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Théry C, Rescigno M, Saito T, 
Verbeek S, Bonnerot C, Ricciardi-Castagnoli P, et al. Fcγ Receptor–mediated 
Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class 
I–restricted Antigen Presentation after Immune Complex Internalization. Journal of 
Experimental Medicine. 1999;189(2):371-80. 
 
 63 
188. Hoffmann E, Kotsias F, Visentin G, Bruhns P, Savina A, and Amigorena S. 
Autonomous phagosomal degradation and antigen presentation in dendritic cells. 
Proc Natl Acad Sci U S A. 2012;109(36):14556-61. 
189. Bánki Z, Krabbendam L, Klaver D, Leng T, Kruis S, Mehta H, Müllauer B, Orth-
Höller D, Stoiber H, Willberg CB, et al. Antibody opsonization enhances MAIT cell 
responsiveness to bacteria via a TNF-dependent mechanism. Immunology and cell 
biology. 2019;97(6):538-51. 
190. Boulouis C, Gorin J-B, Dias J, Bergman P, Leeansyah E, and Sandberg JK. 
Opsonization-Enhanced Antigen Presentation by MR1 Activates Rapid 
Polyfunctional MAIT Cell Responses Acting as an Effector Arm of Humoral 
Antibacterial Immunity. The Journal of Immunology. 2020;205(1):67-77. 
191. Krapp S, Mimura Y, Jefferis R, Huber R, and Sondermann P. Structural Analysis of 
Human IgG-Fc Glycoforms Reveals a Correlation Between Glycosylation and 
Structural Integrity. Journal of Molecular Biology. 2003;325(5):979-89. 
192. Naegeli A, Bratanis E, Karlsson C, Shannon O, Kalluru R, Linder A, Malmström J, 
and Collin M. Streptococcus pyogenes evades adaptive immunity through specific 
IgG glycan hydrolysis. Journal of Experimental Medicine. 2019;216(7):1615-29. 
193. Weiser JN, Ferreira DM, and Paton JC. Streptococcus pneumoniae: transmission, 
colonization and invasion. Nat Rev Microbiol. 2018. 
194. Jochems SP, Marcon F, Carniel BF, Holloway M, Mitsi E, Smith E, Gritzfeld JF, 
Solórzano C, Reiné J, Pojar S, et al. Inflammation induced by influenza virus impairs 
human innate immune control of pneumococcus. Nature Immunology. 
2018;19(12):1299-308. 
195. Bhorat AaE, Madhi SA, Laudat F, Sundaraiyer V, Gurtman A, Jansen KU, Scott DA, 
Emini EA, Gruber WC, and Schmoele-Thoma B. Immunogenicity and safety of the 
13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to 
pneumococcal vaccination. Aids. 2015;29(11):1345-54. 
196. Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, Milito C, 
Trombetta AC, Visentini M, Martini H, et al. Effectiveness of immunoglobulin 
replacement therapy on clinical outcome in patients with primary antibody 
deficiencies: results from a multicenter prospective cohort study. Journal of clinical 
immunology. 2011;31(3):315-22. 
197. Wilson R, Cohen JM, Reglinski M, Jose RJ, Chan WY, Marshall H, de Vogel C, 
Gordon S, Goldblatt D, Petersen FC, et al. Naturally Acquired Human Immunity to 
Pneumococcus Is Dependent on Antibody to Protein Antigens. PLoS Pathog. 
2017;13(1):e1006137. 
198. Gordon SB, Irving GR, Lawson RA, Lee ME, and Read RC. Intracellular trafficking 
and killing of Streptococcus pneumoniae by human alveolar macrophages are 
influenced by opsonins. Infect Immun. 2000;68(4):2286-93. 
199. Zangenah S, Björkhem-Bergman L, Norlin A-C, Hansen S, Lindqvist L, Henriques-
Normark B, and Bergman P. The Pneumocell-study: Vaccination of IgG1- and IgG2-
deficient patients with Prevnar13. Vaccine. 2017;35(20):2654-60. 
200. Cohen C, von Mollendorf C, de Gouveia L, Lengana S, Meiring S, Quan V, 
Nguweneza A, Moore DP, Reubenson G, Moshe M, et al. Effectiveness of the 13-
valent pneumococcal conjugate vaccine against invasive pneumococcal disease in 
 
64 
South African children: a case-control study. The Lancet Global health. 
2017;5(3):e359-e69. 
201. Schmoele-Thoma B, van Cleeff M, Greenberg RN, Gurtman A, Jones TR, 
Sundaraiyer V, Gruber WC, and Scott DA. Persistence of antibodies 1 year after 
sequential administration of the 13-valent pneumococcal conjugate vaccine and the 
23-valent pneumococcal polysaccharide vaccine in adults. Hum Vaccin Immunother. 
2019;15(3):575-83. 
202. Greene JM, Dash P, Roy S, McMurtrey C, Awad W, Reed JS, Hammond KB, 
Abdulhaqq S, Wu HL, Burwitz BJ, et al. MR1-restricted mucosal-associated invariant 
T (MAIT) cells respond to mycobacterial vaccination and infection in nonhuman 
primates. Mucosal Immunology. 2016;10(3):802-13. 
203. Provine NM, Amini A, Garner LC, Spencer AJ, Dold C, Hutchings C, Silva Reyes L, 
FitzPatrick MEB, Chinnakannan S, Oguti B, et al. MAIT cell activation augments 
adenovirus vector vaccine immunogenicity. Science. 2021;371(6528):521-6. 
204. Boulouis C, Sia WR, Gulam MY, Teo JQM, Png YT, Phan TK, Mak JYW, Fairlie 
DP, Poon IKH, Koh TH, et al. Human MAIT cell cytolytic effector proteins synergize 
to overcome carbapenem resistance in Escherichia coli. PLoS Biol. 
2020;18(6):e3000644. 
205. McSharry BP, Samer C, McWilliam HEG, Ashley CL, Yee MB, Steain M, Liu L, 
Fairlie DP, Kinchington PR, McCluskey J, et al. Virus-Mediated Suppression of the 
Antigen Presentation Molecule MR1. Cell Reports. 2020;30(9):2948-62.e4. 
206. Krismer B, Weidenmaier C, Zipperer A, and Peschel A. The commensal lifestyle of 
Staphylococcus aureus and its interactions with the nasal microbiota. Nature Reviews 
Microbiology. 2017;15(11):675-87. 
207. Salgado-Pabón W, and Schlievert PM. Models matter: the search for an effective 
Staphylococcus aureus vaccine. Nature Reviews Microbiology. 2014;12(8):585-91. 
208. Monaco M, Pimentel de Araujo F, Cruciani M, Coccia EM, and Pantosti A. 
Worldwide Epidemiology and Antibiotic Resistance of Staphylococcus aureus. 
Current topics in microbiology and immunology. 2017;409(21-56. 
209. Belkaid Y, and Tamoutounour S. The influence of skin microorganisms on cutaneous 
immunity. Nature Reviews Immunology. 2016;16(6):353-66. 
210. Shaler CR, Choi J, Rudak PT, Memarnejadian A, Szabo PA, Tun-Abraham ME, 
Rossjohn J, Corbett AJ, McCluskey J, McCormick JK, et al. MAIT cells launch a 
rapid, robust and distinct hyperinflammatory response to bacterial superantigens and 
quickly acquire an anergic phenotype that impedes their cognate antimicrobial 
function: Defining a novel mechanism of superantigen-induced immunopathology 
and immunosuppression. PLOS Biology. 2017;15(6). 
211. Alonzo F, 3rd, Kozhaya L, Rawlings SA, Reyes-Robles T, DuMont AL, Myszka DG, 
Landau NR, Unutmaz D, and Torres VJ. CCR5 is a receptor for Staphylococcus 
aureus leukotoxin ED. Nature. 2013;493(7430):51-5. 
212. Alonzo Iii F, Benson MA, Chen J, Novick RP, Shopsin B, and Torres VJ. 
Staphylococcus aureus leucocidin ED contributes to systemic infection by targeting 




213. Reyes-Robles T, Alonzo F, 3rd, Kozhaya L, Lacy DB, Unutmaz D, and Torres VJ. 
Staphylococcus aureus leukotoxin ED targets the chemokine receptors CXCR1 and 
CXCR2 to kill leukocytes and promote infection. Cell Host Microbe. 2013;14(4):453-
9. 
214. Lubkin A, Lee WL, Alonzo F, Wang C, Aligo J, Keller M, Girgis NM, Reyes-Robles 
T, Chan R, O’Malley A, et al. Staphylococcus aureus Leukocidins Target Endothelial 
DARC to Cause Lethality in Mice. Cell Host & Microbe. 2019;25(3):463-70.e9. 
215. Spaan AN, Reyes-Robles T, Badiou C, Cochet S, Boguslawski KM, Yoong P, Day 
CJ, de Haas CJ, van Kessel KP, Vandenesch F, et al. Staphylococcus aureus Targets 
the Duffy Antigen Receptor for Chemokines (DARC) to Lyse Erythrocytes. Cell Host 
Microbe. 2015;18(3):363-70. 
216. Radcliff FJ, Waldvogel-Thurlow S, Clow F, Mahadevan M, Johnston J, Li G, Proft T, 
Douglas RG, and Fraser JD. Impact of Superantigen-Producing Bacteria on T Cells 
from Tonsillar Hyperplasia. Pathogens. 2019;8(3):90. 
217. Genardi S, Visvabharathy L, Cao L, Morgun E, Cui Y, Qi C, Chen Y-H, Gapin L, 
Berdyshev E, and Wang C-R. Type II Natural Killer T Cells Contribute to Protection 
Against Systemic Methicillin-Resistant Staphylococcus aureus Infection. Frontiers in 
Immunology. 2020;11( 
218. Leland McInnes JH, James Melville. UMAP: Uniform Manifold Approximation and 
Projection for Dimension Reduction. arXivorg. 2020. 
219. Kim JH, Chaurasia AK, Batool N, Ko KS, and Kim KK. Alternative Enzyme 
Protection Assay To Overcome the Drawbacks of the Gentamicin Protection Assay 
for Measuring Entry and Intracellular Survival of Staphylococci. Infect Immun. 
2019;87(5). 
220. Cichocki F, Grzywacz B, and Miller JS. Human NK Cell Development: One Road or 
Many? Frontiers in Immunology. 2019;10( 
221. Small C-L, McCormick S, Gill N, Kugathasan K, Santosuosso M, Donaldson N, 
Heinrichs DE, Ashkar A, and Xing Z. NK Cells Play a Critical Protective Role in 
Host Defense against Acute ExtracellularStaphylococcus aureusBacterial Infection in 
the Lung. The Journal of Immunology. 2008;180(8):5558-68. 
222. Miller LS, and Cho JS. Immunity against Staphylococcus aureus cutaneous 
infections. Nature Reviews Immunology. 2011;11(8):505-18. 
223. O’Brien EC, and McLoughlin RM. Considering the ‘Alternatives’ for Next-
Generation Anti-Staphylococcus aureus Vaccine Development. Trends in Molecular 
Medicine. 2019;25(3):171-84. 
224. Diep BA, Le VTM, Visram ZC, Rouha H, Stulik L, Dip EC, Nagy G, and Nagy E. 
Improved Protection in a Rabbit Model of Community-Associated Methicillin-
Resistant Staphylococcus aureus Necrotizing Pneumonia upon Neutralization of 
Leukocidins in Addition to Alpha-Hemolysin. Antimicrobial Agents and 
Chemotherapy. 2016;60(10):6333-40. 
225. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Migaud M, Israel L, 
Chrabieh M, Audry M, et al. Chronic mucocutaneous candidiasis in humans with 
inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65-8. 
226. Ortines RV, Wang Y, Liu H, Dikeman DA, Pinsker BL, Miller RJ, Kim SE, 
Ackerman NE, Rizkallah JF, Marcello LT, et al. Efficacy of a Multimechanistic 
 
66 
Monoclonal Antibody Combination against Staphylococcus aureus Surgical Site 
Infections in Mice. Antimicrobial Agents and Chemotherapy. 2019;63(8). 
227. Rouha H, Weber S, Janesch P, Maierhofer B, Gross K, Dolezilkova I, Mirkina I, 
Visram ZC, Malafa S, Stulik L, et al. Disarming Staphylococcus aureus from 
destroying human cells by simultaneously neutralizing six cytotoxins with two human 
monoclonal antibodies. Virulence. 2017;9(1):231-47. 
228. Vu TTT, Nguyen NTQ, Tran VG, Gras E, Mao Y, Jung DH, Tkaczyk C, Sellman BR, 
and Diep BA. Protective Efficacy of Monoclonal Antibodies Neutralizing Alpha-
Hemolysin and Bicomponent Leukocidins in a Rabbit Model of Staphylococcus 
aureus Necrotizing Pneumonia. Antimicrobial Agents and Chemotherapy. 2020;64(3). 
229. Takaya A, Yamamoto T, and Tokoyoda K. Humoral Immunity vs. Salmonella. Front 
Immunol. 2019;10(3155. 
230. Leung DT, Bhuiyan TR, Nishat NS, Hoq MR, Aktar A, Rahman MA, Uddin T, Khan 
AI, Chowdhury F, Charles RC, et al. Circulating Mucosal Associated Invariant T 
Cells Are Activated in Vibrio cholerae O1 Infection and Associated with 
Lipopolysaccharide Antibody Responses. PLOS Neglected Tropical Diseases. 
2014;8(8):e3076. 
231. Kim J, Kim Y, Abdelazem AZ, Kim HJ, Choo H, Kim HS, Kim JO, Park Y-J, and 
Min S-J. Development of carbapenem-based fluorogenic probes for the clinical 
screening of carbapenemase-producing bacteria. Bioorganic Chemistry. 
2020;94(103405. 
232. Barathan M, Mohamed R, Vadivelu J, Chang LY, Saeidi A, Yong YK, Ravishankar 
Ram M, Gopal K, Velu V, Larsson M, et al. Peripheral loss of 
CD8+CD161++TCRVα7·2+mucosal-associated invariant T cells in chronic hepatitis 
C virus-infected patients. European Journal of Clinical Investigation. 
2016;46(2):170-80. 
233. Ibidapo-obe O, Stengel S, Köse-Vogel N, Quickert S, Reuken PA, Busch M, Bauer 
M, Stallmach A, and Bruns T. Mucosal-Associated Invariant T Cells Redistribute to 
the Peritoneal Cavity During Spontaneous Bacterial Peritonitis and Contribute to 
Peritoneal Inflammation. Cellular and Molecular Gastroenterology and Hepatology. 
2020;9(4):661-77. 
